WO2009054914A1 - Compositions and methods for treatment of diabetic retinopathy - Google Patents

Compositions and methods for treatment of diabetic retinopathy Download PDF

Info

Publication number
WO2009054914A1
WO2009054914A1 PCT/US2008/011878 US2008011878W WO2009054914A1 WO 2009054914 A1 WO2009054914 A1 WO 2009054914A1 US 2008011878 W US2008011878 W US 2008011878W WO 2009054914 A1 WO2009054914 A1 WO 2009054914A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
aryl
lfa
substituted
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/011878
Other languages
English (en)
French (fr)
Inventor
John Burnier
Thomas Gadek
Charles Semba
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sarcode Bioscience Inc
Original Assignee
Sarcode Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarcode Corp filed Critical Sarcode Corp
Priority to EP20189143.9A priority Critical patent/EP3797775A1/en
Priority to EP16204718.7A priority patent/EP3167886B1/en
Priority to MX2010004281A priority patent/MX2010004281A/es
Priority to CA2702984A priority patent/CA2702984C/en
Priority to CN200880117716A priority patent/CN101873797A/zh
Priority to ES08842113.6T priority patent/ES2630406T3/es
Priority to JP2010529955A priority patent/JP5808037B2/ja
Priority to EP08842113.6A priority patent/EP2209371B1/en
Priority to AU2008317473A priority patent/AU2008317473B2/en
Publication of WO2009054914A1 publication Critical patent/WO2009054914A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/164—Retinal disorders, e.g. retinopathy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • a method to treat diabetic retinopathy in a subject comprising performing a diabetic retinopathy diagnostic test on said subject; determining whether said subject suffers from diabetic retinopathy based on the results of said diagnostic test; and upon diagnosis of said diabetic retinopathy, administering to said subject an effective amount of a (LFA-I) antagonist in a pharmaceutically acceptable formulation.
  • the compound of Formula II is provided which contains a stereochemistry as in Formula I!'.
  • an LFA antagonist is provided which is a compound of Formula IA, HA or IIB.
  • the therapeutic agent is administered in a carrier vehicle which is liquid drops, liquid wash, nebulized liquid, gel, ointment, aerosol, spray, polymer micro and nanoparticles, solution, suspension, solid, biodegradable matrix, powder, crystals, foam, or liposomes.
  • topical administration comprises infusion of said compound to said eyes via a device selected from the group consisting of a pump-catheter system, an insert, a continuous or selective release device, a bioabsorbable implant, a continuous or sustained release formulation, and a contact lens.
  • the pharmaceutical composition comprises a therapeutic agent which inhibits the interaction of LFA-I and an ICAM, which is a compound of Formula I, II, III, IV, V, VI, VII, VHI, IX, X, or XI.
  • the pharmaceutical composition is suitable for topical administration.
  • the pharmaceutical composition is suitable for administration via injection.
  • the pharmaceutical composition is suitable for administration suitable for administration as an implant.
  • compounds are provided for use in the methods of the invention.
  • Compounds that are useful in the methods of the invention include antibodies, fragments of antibodies, polypeptides, peptides, polymers, and organic small molecules.
  • the antibody Raptiva is used in an ocular formulation to treat diabetic retinopathy.
  • Figure 2 depicts antigen activation of the LFA-I :IC AM-I interaction.
  • Figure 9 depicts the effect of antagonists on ligand binding in the LFA- 1 /ICAM- 1 and LFA- 1 /small molecule ELISAs.
  • Figure 10 depicts Schild regressions of sIC AM-I and compound 3 antagonism.
  • Figure 11 is a graphical representation of the effect of a directly competitive LFA-I antagonist of the invention upon the release of inflammatory cytokines, in human mononucleocytes (PBMC) stimulated with staphylococcal enterotoxin B (SEB) as compared to the effect of cyclosporine-A (CsA).
  • Figure 12 is a graphical representation of the distribution into the eye via topical application of a 14 C labeled directly competitive LFA-I antagonist of the invention at a 30 minute timepoint and a 4 hour timepoint after administration, as measured by detection of the radiolabel.
  • Attraction and adhesion of leukocytes to the vascular wall by the inflammatory process cause leukocytes to adhere temporarily to the endothelium (leukostasis), release cytotoxic factors, and injure or kill the endothelial cell.
  • the damaged endothelial surface initiates platelet adherence, aggregation, microthrombi formation, vascular occlusion and ischemia.
  • Another consequence of endothelial injury is alteration in the Blood -Retinal Barrier (BRB) causing increased vascular permeability. This can be evidenced by fluorescein leakage during fluorescein angiography or retinal thickening assessed by optical coherence tomography (OCT).
  • Consequences of this leakage can be clinically significant macular edema and deposition of lipoproteins in the retina (hard exudates) contributing to retinal thickening .
  • retinal ganglion cells are lost leading towards visual loss or blindness.
  • the disrupted autoregulation and decreased retinal blood flow resulting from the changes in vasculature in endothelial cells, pericyte death, and capillary obliteration are markers for progression of DR, and leads to development of retinal ischemia, which enables development of the more severe, proliferative stage of DR.
  • Proliferative DR involves neovascularization or angiogenesis, induced by retinal ischemia of the disc or other locations of the retina. This new vasculature can cause hemorrhage of the vitreous humour and retinal detachments from accompanying contractile fibrous tissue.
  • macular edema or diabetic macular edema At any point during this progression of diabetic retinopathy, macular edema or diabetic macular edema
  • Laser treatment may also cause persistent or recurrent hemorrhage, increase the risk of retinal detachment, or induce neovascularization or fibrosis.
  • Other treatment options for ocular-related disorders include thermotherapy, vitrectomy, photodynamic therapy, radiation therapy, surgery, e.g., removal of excess ocular tissue, and the like.
  • all available treatment options have limited therapeutic effect, require repeated, costly procedures, and/or are associated with dangerous side-effects.
  • ICAM- 1 and LFA- 1 (LFA- 1 is also referred to as ⁇ L ⁇ 2 and CD 11 a/CD 18) has been shown to be involved in the processes of adhesion, leukocyte transendothelial migration, migration to sites of injury, and proliferation of lymphocytes at the activated target site, as shown in Figure 1.
  • LFA- 1 LFA- 1 is also referred to as ⁇ L ⁇ 2 and CD 11 a/CD 18
  • cytokines/chemokines activate integrins constitutively expressed on leukocytes.
  • Blood vessel endothelial cells also upregulate ICAM-I in response to the presence of the same cytokines/chemokines.
  • LFA-I plays a role in creating and maintaining the immunological synapse, which may be defined as the physical structure of the interacting surfaces of T cells and Antigen Presenting Cells (APCs), as shown in Figure 2. LFA-I stabilizes T-cell engagement with the APC, and thus leads to activation of T cells. The interaction of LFA-I and ICAM-I also appears to provide co-stimulatory signals to resting T cells, as shown in Figure 3. CD4+ T-cell proliferation and cytokine synthesis are mediated by this interaction as part of the inflammatory response.
  • APCs Antigen Presenting Cells
  • ICAM-I and LFA-I Given the role that the interaction of ICAM-I and LFA-I plays in immune/inflammatory response, it is desirable to modulate these interactions to achieve a desired therapeutic result (e. g., inhibition of the interaction in the event of an overactive inflammatory response). Also, since LFA-I has several ligand partners within the ICAM family (ICAM-I, ICAM-2 and ICAM-3), involving a number of signaling pathways, in some embodiments of the invention, it is desirable to modulate these interactions selectively. In some embodiments of the invention, therapeutic agents are provided that will interfere with the association of LFA-I with ICAM-I, ICAM-2, and/or ICAM-3 to thus modulate the respective signaling pathways for each pair of interactions.
  • the invention provides therapeutic agents that interfere with the association of LFA-I with ICAM-I, which can block the adhesion, migration, proliferation, and release of inflammatory signals to surrounding tissue by immune system cells.
  • the invention provides methods of administering a therapeutic agent which inhibits the interaction between LFA-I and an ICAM,
  • the therapeutic agent binds to either LFA-I or binds to an ICAM.
  • the invention provides therapeutic agents that bind to LFA-I to inhibit the association of LFA-I with ICAM-I, ICAM-2, and/or ICAM-3 thus acting as LFA-I antagonists.
  • the therapeutic agent provided by the invention is an allosteric antagonist and is a competitive but not directly competitive antagonist of LFA-I.
  • the therapeutic agents are useful in treating diabetic retinopathy and disorders associated with that condition. ⁇ . Compounds Useful in the Method.
  • alkyl encompass both substituted and unsubstituted groups.
  • lower alkyl is used to indicate those alkyl groups (substituted, unsubstituted, branched or unbranched) having about 1-6 carbon atoms.
  • the alkyl, alkenyl and alkynyl groups employed in the invention contain about 1- 20 aliphatic carbon atoms. In certain other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the invention contain about 1-10 aliphatic carbon atoms.
  • alkoxy examples include but are not limited to, methoxy, ethoxy, isopropoxy, n-butoxy, i-butoxy, sec-butoxy, tert-butoxy, neopentoxy, n- hexloxy and the like.
  • lower alkoxy refers to a lower alkyl as defined above which may be branched or unbranched as also defined above and which is bonded by an oxygen to another group (i.e. alkyl ethers).
  • thioalkyl refers to a saturated or unsaturated (i.
  • heteromatic moiety refers to a planar ring comprising at least one heteroatom, having p-orbitals perpendicular to the plane of the ring at each ring atom, and satisfying the Huckel rule where the number of pi electrons in the ring is (4n+2) wherein n is an integer.
  • aryl and heteroaryl groups can be unsubstituted or substituted, wherein substitution includes replacement of one or more of the hydrogen atoms thereon independently with any one or more of the following moieties including, but not limited to: aliphatic; alicyclic ; heteroaliphatic; heterocyclic; aromatic; heteroaromatic; aryl; heteroaryl; alkylaryl; heteroalkylaryl; alkylheteroaryl; heteroalkylheteroaryl; alkoxy; aryloxy ; heteroalkoxy; heteroaryloxy; alkylthio; arylthio; heteroalkylthio; heteroarylthio; F; Cl ; Br; I; -OH; -NO 2 ; -CN; -CF 3 ; -CH 2 CF 3 ; -CHCl 2 ; -CH 2 OH; -CH 2 CH 2 OH; -CH 2 NH 2
  • any two adjacent groups taken together may represent a 4, 5, 6, or 7-membered substituted or unsubstituted alicyclic or heterocyclic moiety. Additional examples of generally applicable substituents are illustrated by the specific embodiments shown in the Examples that are described herein.
  • cycloalkyl refers specifically to groups having three to seven, preferably three to ten carbon atoms. Suitable cycloalkyls include, but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like, which, as in the case of aliphatic, alicyclic, heteroaliphatic or heterocyclic moieties, may optionally be substituted with substituents including, but not limited to aliphatic; alicyclic; heteroaliphatic; heterocyclic; aromatic ; heteroaromatic; aryl; heteroaryl; alkylaryl; heteroalkylaryl; alkylheteroaryl ; heteroalkylheteroaryl; alkoxy; aryloxy ; heteroalkoxy; heteroaryloxy ; alkylthio; heteroarylthio; F; Cl ; Br; I; -OH; - NO
  • R x independently includes, but is not limited to, aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic, heteroaromatic, aryl, heteroaryl, alkylaryl, alkylheteroaryl, heteroalkylaryl or heteroalkylheteroaryl, wherein any of the aliphatic, alicyclic, heteroaliphatic, heterocyclic, alkylaryl, or alkylheteroaryl substituents described above and herein may be substituted or unsubstituted, branched or unbranched, saturated or unsaturated, and wherein any of the aromatic, heteroaromatic, aryl or heteroaryl substituents described above and herein
  • heteroaliphatic refers to aliphatic moieties in which one or more carbon atoms in the main chain have been substituted with a heteroatom.
  • a heteroaliphatic group refers to an aliphatic chain which contains one or more oxygen, sulfur, nitrogen, phosphorus or silicon atoms, e. place of carbon atoms.
  • Heteroaliphatic moieties may be linear or branched, and saturated or unsaturated.
  • heterocycloalkyl refers to compounds which combine the properties of heteroaliphatic and cyclic compounds and include, but are not limited to, saturated and unsaturated mono-or polycyclic cyclic ring systems having 5-16 atoms wherein at least one ring atom is a heteroatom selected from S and N (wherein the nitrogen and sulfur heteroatoms may be optionally be oxidized), wherein the ring systems are optionally substituted with one or more functional groups, as defined herein.
  • heterocycloalkyl refers to a non-aromatic 5-, 6-or 7- membered ring or a polycyclic group wherein at least one ring atom heteroatom selected from S and N (wherein the nitrogen and sulfur heteroatoms may be optionally be oxidized), including, but not limited to, a bi-or tri-cyclic group, comprising fused six-membered rings having between one and three heteroatoms independently selected from oxygen, sulfur and nitrogen, wherein (i) each 5-membered ring has 0 to 2 double bonds, each 6-membered ring has 0 to 2 double bonds and each 7-membered ring has 0 to 3 double bonds, (ii) the nitrogen and sulfur heteroatoms may be optionally be oxidized, (iii) the nitrogen heteroatom may optionally be quaternized, and (iv) any of the above heterocyclic rings may be fused to an aryl or heteroaryl
  • heterocycles include, but are not limited to, heterocycles such as furanyl, pyranyl, pyrrolyl, thienyl, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, oxazolyl, oxazolidinyl, isooxazolyl, isoxazolidinyl, dioxazolyl, thiadiazolyl, oxadiazolyl, tetrazolyl, triazolyl, thiatriazolyl, thiadiazolyl, oxadiazolyl, mo ⁇ holinyl, thiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, dithiazolyl, dithiazolidinyl, tetrahydrofiiryl, and benzofused derivatives thereof.
  • haloalkyl denotes an alkyl group, as defined above, having one, two, or three halogen atoms attached thereto and is exemplified by such groups as chloromethyl, bromoethyl, trifluoromethyl, and the like.
  • amino refers to a primary (-NH 2 ), secondary (-NHR x ), tertiary (-NR 1 R y ), or quaternary amine (-N + R x R y R 2 ), where R y and R z are independently an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic or heteroaromatic moiety, as defined herein.
  • amino groups include, but are not limited to, methylamino, dimethylamino, ethylamino, diethylamino, diethylaminocarbonyl, iso-propylamino, piperidino, trimethylamino, and propylamino.
  • C I-6 alkylidene refers to a substituted or unsubstituted, linear or branched saturated divalent radical consisting solely of carbon and hydrogen atoms, having from one to six carbon atoms, having a free valence "-" at both ends of the radical.
  • heterocycloalkyl refers to any one of the common, naturally occurring L-amino acids found in naturally occurring proteins : glycine (GIy), alanine (Ala), valine (VaI), leucine (Leu), isoleucine
  • side chain R is other than the amino acid side chains occurring in nature.
  • amino acid encompasses natural amino acids and unnatural amino acids.
  • bioisosteres generally refers to two or more compounds or moieties that possess similar molecular shapes and/or volumes. In certain embodiments, bioisosteres have approximately the same distribution of electrons. In certain other embodiments, bioisosteres exhibit similar biological properties. In preferred embodiments, bioisosteres possess similar molecular shapes and volumes; have approximately the same distribution of electrons; and exhibit similar biological properties.
  • Pro-drugs of a variety of compounds, and materials and methods for derivatizing the parent compounds to create the pro-drugs, are known and may be adapted to the present invention. Certain exemplary pharmaceutical compositions and pharmaceutically acceptable derivatives will be discussed in more detail herein below.
  • the term pharmaceutically acceptable salt refers to those salts which are suitable for pharmaceutical use , preferably for use in the tissues of humans and lower animals without undue irritation, allergic response and the like.
  • Pharmaceutically acceptable salts of amines, carboxylic acids, and other types of compounds are well known in the art. For example, S. M. Berge, et al. .describe pharmaceutically acceptable salts in detail in J Pharmaceutical Sciences, 66: 1-19 (1977), incorporated herein by reference.
  • the salts can be prepared in situ during the final isolation and purification of the compounds of the invention, or separately by reacting a free base or free acid function with a suitable reagent, as described generally below.
  • a free base function can be reacted with a suitable acid.
  • suitable pharmaceutically acceptable salts thereof may, include metal salts such as alkali metal salts, e. g. sodium or potassium salts; and alkaline earth metal salts, e. g. calcium or magnesium salts.
  • Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid
  • organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
  • salts include adipate, alginate, ascorbate, aspartate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hernisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pectinate, persulfate, 3- phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate
  • alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
  • Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, sulfonate and aryl sulfonate.
  • ester refers to esters that hydrolyze in vivo and include those that break down readily in the human body to leave the parent compound or a salt thereof.
  • Suitable ester groups include, for example, those derived from pharmaceutically acceptable aliphatic alcohol compounds, particularly alkanes, alkenes, ehtylene glycol, cycloalkanes, and the like in which each alkyl or alkenyl moiety advantageously has not more than 6 carbon atoms. These are exemplary only and in no way limit the possibilities of esters known in the art.
  • prodrugs refers to those prodrugs of the compounds of the present invention which are suitable for pharmaceutical use, preferably for use with the tissues of humans and lower animals with undue toxicity, irritation, allergic response, and the like, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention.
  • prodrug refers to compounds that are rapidly transformed in vivo to yield the parent compound of the above formula, for example by hydrolysis in blood. A thorough discussion is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the A. C. S. Symposium Series, and in Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference.
  • the site of crosslinking was further defined by fragmenting the affinity-labeled ⁇ L subunit with hydroxylamine, electrophoretically separating the fragments, and then performing N-terminal sequencing on the radiolabeled fragments to determine their locations within the protein sequence. Two sequences were identified, the first starting with residue 1 (sequence found: YNLD VRGARSFS (SEQ ID NO I)) and the second with residue 30 (sequence found: GVTVGAPGEGNST (SEQ ID NO 2)).
  • the binding site responsible for the stabilization of LFA-I to SDS-PAGE may reside in the I-like domain of the ⁇ subunit. As shown above, this ⁇ subunit binding site is not related to the high affinity binding site in the ⁇ subunit which is responsible for the direct competitive inhibition of ICAM-I binding. However, the ⁇ subunit binding site responsible for LFA-I stabilization by compound 3 may be the same as the low affinity ⁇ subunit crosslinking site.
  • the second site is a lower affinity binding site (e.g. Kj > 1 ⁇ M) in the ⁇ subunit which is involved with stabilization of the LFA-I heterodimer under SDS-PAGE. This site is more dynamic by nature (i.e.
  • the common trend in potencies between the two antagonist competition ELISAs with ICAM-I-Ig and compound 2B as ligands reveals that each compound disrupts the binding of both ICAM-I and small molecule ligands in a mechanistically similar fashion.
  • the antagonists were added in two-fold dilutions starting at 2.4 (A) and 2.7 (B) ⁇ M sICAM-1, 0.040 (C) and 0.10 (D) ⁇ M compound 3 and 20 (E) and 50 (F) ⁇ M A-286982.
  • the order of antagonist concentrations was, -TT (lowest added antagonist concentration), - ⁇ -, - O-, - ⁇ -, - ⁇ -, -A- to -•- (highest antagonist concentration).
  • the fits of the data are shown as the solid lines. The data shown are from one plate and are representative of a minimum of two experiments.
  • ICAM-I-Ig binding may be due to the known allosteric effect of the compound binding to the IDAS site on LFA-I.
  • the A-286982 binding data serve as an illustration for allosteric inhibition for small molecule and protein ligand binding to LFA-I in the binding experiments demonstrated in this method.
  • Schild analysis can be also used to investigate whether a compound inhibits ligand binding through direct competition for a single binding site. This model is based upon the assumptions that equiactive responses in an assay are the result of equivalent occupancy of receptor by ligand and that maximal binding is unchanged by the presence of antagonist.
  • the dose ratio is the ratio of the EC 50 values in the presence and absence of antagonist and is a measure of the ligand concentrations leading to equiactive responses. This dose ratio was determined for each concentration of antagonist and the Schild regressions were plotted as shown in Figure 10. A linear response with a slope of 1 in a Schild regression indicates that inhibition by an antagonist is directly competitive and reversible. The Schild analysis would yield a nonlinear relationship and/or a slope that deviates significantly from 1 in the case of an allosteric inhibitor that does not result in a reduction of maximal binding. The Schild regressions for both sICAM-1 and compound 3 are shown in Figure 10 with comparable slopes of 1.26 and 1.24, respectively.
  • ICAM-I Blocking of the ICAMs, such as for example ICAM-I, or the leukointegrins, such as for example, LFA-I, by antibodies directed against either or both of these molecules can inhibit inflammatory response.
  • Previous studies have investigated the effects of anti-CDl Ia MAbs on many T-cell- dependent immune functions in vitro and a number of immune responses in vivo. In vitro, anti-CDl Ia MAbs inhibit T-cell activation (See Kuypers T. W., Roos D. 1989 "Leukocyte membrane adhesion proteins LFA-I, CR3 and pl50,95: a review of functional and regulatory aspects" Res.
  • a number of antibodies which are directed against LFA-I may be used to treat diabetic retinopathy, including efalizumab (Raptiva) .
  • Peptides have been investigated for use in reducing the interaction of LFA-I with ICAM-I.
  • Polypeptides that do not contain an Fc region of an IgG are described in U. S. Patent No. 5,747,035, which can be used to treat LFA-I mediated disorders, in particular diabetic retinopathy.
  • Use of dual peptides, the first a modulator of ICAM-I and the second a blocking peptide with a sequence obtained from LFA-I is described in U.S. Patent No. 5,843,885 to reduce the interactions between LFA-I and ICAM-I.
  • Cyclic peptides have been described in U.S. Patent No. 6,630,447 as inhibitors of the LFA-I: ICAM-I interaction.
  • Small organic molecule generally is used to refer to organic molecules of a size comparable to those organic molecules generally used in pharmaceuticals.
  • the term typically excludes organic biopolymers (e.g., proteins, nucleic acids, etc.). Small organic molecules most often range in size up to about 5000 Da, in some embodiments, up to about 2000 Da, or in other embodiments, up to about 1000 Da.
  • compounds useful in the methods of the present invention include compounds of Formula I:
  • each occurrence of R 3A is independently hydrogen, a protecting group, an aliphatic, alicyclic, heteroaliphatic, heteroalicyclic, aryl, heteroaryl, alkylaryl, alkylheteroaryl, heteroalkylaryl, heteroalkylheteroaryl moiety, or a pharmaceutically acceptable salt or ester, or R 3A , taken together with R 1 and R 2 , forms a heterocyclic moiety; wherein X 0 is a halogen selected from F, Br or I;
  • Formula IA Formula HA Formula IIB where R 17 is hydrogen, pharmaceutically acceptable salts or esters, and R 27 is as in Formula II.
  • R 17 is hydrogen, pharmaceutically acceptable salts or esters, and R 27 is as in Formula II.
  • Compounds of this class are disclosed in U. S Patent No. 7314938.
  • Cy is a 3-5 member ring.
  • Cy is a 5-member non-aromatic heterocycle optionally substituted with hydroxyl, oxo, thio, Cl, CM alkyl (preferably methyl), or C ⁇ alkanoyl (preferably acetyl, propanoyl or butanoyl).
  • the non-aromatic heterocycle is selected from the group consisting of piperidine, piperazine, morpholine, tetrahydrofuran, tetrahydrothiophene, oxazolidine, thiazolidine optionally substituted with hydroxy, oxo, mercapto, thio, alkyl or alkanoyl.
  • Cy is a non-aromatic heterocycle selected from the group consisting of tetrahydrofuran-2-yl, thiazolidin-5-yl, thiazolidin-2-one-5-yl, and thiazolidin-2-thione-5-yl and pyrrolidine.
  • the aromatic or heterocycle comprises one or heteroatoms (N, O or S) and is optionally substituted with hydroxyl, oxo, mercapto, thio, methyl, acetyl, propanoyl or butyl.
  • X 2 is the group — CH 2 — NR 10 — C(O) — wherein the carbonyl — C(O) — portion thereof is adjacent (i.e. covalently bound) to Cy and R 10 is alkyl i.e. methyl or more preferably H.
  • K is a carbocycle or heterocycle optionally substituted with hydroxyl, mercapto, halogen, oxo, thio, a hydrocarbon, a halo-substituted hydrocarbon, amino, amidine, guanidine, cyano, nitro, alkoxy or acyl.
  • K is aryl or heteroaryl optionally substituted with halogen or hydroxyl.
  • K is phenyl, furan-2-yl, thiophene-2-yl, phenyl substituted with a halogen (preferably Cl) or hydroxyl, preferably at the meta position.
  • L 2 is a divalent hydrocarbon optionally having one or more carbon atoms replaced with N, O, S, SO or SO 2 and optionally being substituted with hydroxyl, halogen oxo, or thio; or three carbon atoms of the hydrocarbon are replaced with an amino acid residue.
  • L 2 is less than 10 atoms in length and more preferably 5 or less and most preferably 5 or 3 atoms in length.
  • each R 10 is independently H or alkyl and R 16 is an amino acid side chain.
  • Preferred amino acid side chains include non-naturally occurring side chains such as phenyl or naturally occurring side chains. Preferred side chains are those from Phe, Tyr, Ala, GIn and Asn.
  • L 2 is — CH 2 — NR 10 — C(O) — wherein the methylene moiety ( — CH 2 — ) thereof is adjacent to K.
  • R 5 is H, OH, amino, O-carbocycle or alkoxy optionally substituted with amino, a carbocycle, a heterocycle, or a pharmaceutically acceptable salt or ester.
  • R 5 is H, phenyl or Ci -4 alkoxy optionally substituted with a carbocycle such as phenyl.
  • R 5 is H.
  • R 5 is methoxy, ethoxy, propyloxy, butyloxy, isobutyloxy, s-butyloxy, t-butyloxy, phenoxy or benzyloxy.
  • R 5 is NH 2 - 1° a particularly preferred embodiment R 5 is ethoxy.
  • R 5 is isobutyloxy.
  • R 6 and R 7 are independently H, F, Cl, Br or I. In another particular embodiment, R 8 and R 9 are both H. In another particular embodiment, one of R 6 and R 7 is a halogen while the other is hydrogen or a halogen. In a particularly preferred embodiment, R 7 is Cl while R 6 , R 8 and R 9 are each H. In another particularly preferred embodiment, R 6 and R 7 are both Cl while R 8 and R 9 are both H. [00128] R 10 is H or a hydrocarbon chain optionally substituted with a carbocycle or a heterocycle. In a preferred embodiment, R 10 is H or alkyl i.e. methyl, ethyl, propyl, butyl, i-butyl, s-butyl or t-butyl. In a particular embodiment R 10 is H.
  • R is a group of the formula
  • A is hydrogen, hydroxy, amino, or halogen and B is amino, carboxy, hydrogen, hydroxy, cyano, trifluoromethyl, halogen, lower alkyl, or lower alkoxy;
  • R 12 is a group of the formula:
  • R 13 is hydrogen, carboxy, or lower alkyl; n is 0 or 1 ; U 2 , V 2 , and W 2 are independently hydrogen, halogen, or lower alkyl provided U 2 and V 2 are not both hydrogen; X 3 is carbonyl, phenyl-substituted lower alkylene, imino, substituted imino, or sulfonyl; Y 2 is lower alkylene which may be substituted by one or more of amino, substituted amino, lower alkyl, or cyclo lower alkyl, or Y 2 is lower alkenylene or lower alkylenethio; k is 0 or 1; when k is 1, Z 2 is hydrogen, lower alkylthio, — COOH, — CONH 2 , amino; and when k is 0 or 1, Z 2 is 1- adamantyl, diphenylmethyl, 3-[[(5-chloropyridin-2-yl) amino] carbonyl] pyrazin-2-
  • R 14 is a group of the formula:
  • R 15 is hydrogen, carboxy, or lower alkyl
  • U 3 , V 3 , and W 3 are independently hydrogen, halogen; or
  • U 3 , V 3 , and W 3 are lower alkyl provided that U 3 and V 3 are not both hydrogen;
  • X 4 is carbonyl, phenyl-substituted lower alkylene, imino, substituted imino which includes cyano, or sulfonyl;
  • Y 3 is lower alkenylene, lower alkylenethio, or is lower alkylene which may be substituted by amino, acetylamino, or cyclo-lower alkyl;
  • k 2 is 0 or 1 ; when k 2 is 1 , Z is hydrogen, lower alkylthio, — COOH, — CONH 2 — , or amino; when k 2 is 0 or 1, Z 3 is 1-adamantyl, diphenylmethyl, 3-[[(5-chloropyridin-2-yl)amino]carbonyl]pyrazin-2-yl; and when k 2 is 0 or 1, Z may be cycloalkyl
  • R 21 is hydrogen, pharmaceutically acceptable salts or esters thereof.
  • a preferred embodiment of compounds of Formula V has the stereochemistry as indicated in Formula V:
  • L 3 is a bivalent linking group having one of the following structures; [00145] -i ⁇ l ⁇ L 1 -,
  • R 32 , R 32 ', R 34 , R 34 ', R 35 , R 35 ', R 36 , R 36 ', R 37 and R 37 ' each are independently R 38 , R 39 or U-Q-V-W, optionally, R 24 and R 34 ' separately or together may form a saturated, unsaturated or aromatic fused ring with B 3 through a substituent RP on B, the fused ring containing 5, 6 or 7 atoms in the ring and optionally containing 1-3 heteroatoms selected from the group O, S and N, where any S or N may optionally be oxidized; optionally, R 35 and R 35 separately or together and R 36 and R 36 ' separately or together may form a saturated, unsaturated or aromatic fused ring with D 3 through a substituent R 31 on D 3 , the fused ring containing 5, 6 or 7 atoms in the ring and optionally containing 1-3 heteroatoms selected from the group O, S and N, where any S or N may optionally
  • ⁇ - ' is a fused hetero- or homocyclic ring containing 5, 6 or 7 atoms, the ring being unsaturated, partially saturated or aromatic, the heteroatoms selected from 1-3 O, S and N,
  • G 3 is hydrogen or C r C 6 alkyl, optionally G taken together with T may form a C 3 -C 6 cycloalkyl optionally substituted with -V-W;
  • T 3 is one of the following [00159] a naturally occurring ⁇ -amino-acid side chain, [00160] and U 4 -Q 4 -V 4 -W 4 ;
  • het is a mono- or bicyclic 5, 6, 7, 9 or 10 member heterocyclic ring, each ring containing 1-4 heteroatoms selected from N, O and S, where the heterocyclic ring may be saturated, partially saturated, or aromatic and any N or S being optionally oxidized, the heterocyclic ring being substituted with 0-3 R 41 ;
  • R 38 is R 38' or R 38 " substituted with 1-3 R 38 '; where [00173] R 38 ' is hydrogen, halo (F. Cl, Br, I), cyano, isocyanate, carboxy, carboxy-Ci-C u alkyl, amino, amino-C r
  • R 38 " is Co-Ci O alkyl-Q-Co-C 6 alkyl, C o -C, o alkenyl-Q-Co-C 6 alkyl, C o -C 1o alkynyl-Q-Co-C 6 alkyl, C 3 - C 1 ,cycloalkyl-Q-Co-C 6 alkyl, C 3 -Ciocycloalkenyl-Q-C 0 -C 6 alkyl, C,-C 6 alkyl-C 6 -C 12 aryl-Q-C 0 -C 6 alkyl, C 6 -Ci 0 aryl-
  • R 43 is hydrogen and substituted or unsubstituted Ci-Ci O alkyl, C 2 -Ci 0 alkenyl, C 2 -Ci 0 alkynyl, C 3 -
  • R 31 is R 40 or R 41 ;
  • R 41 is OH, OCF 3 , OR 43 , SR 42 , halo(F, Cl. Br, I), CN, isocyanate, NO 2 , CF 3 , C o -C 6 alkyl-NR 3O R 30 ',
  • R 37 and R 38 are each independently hydrogen, alkyl, carboxyalkyl, monoalkylaminocarbonylalkyl, or dialkylaminocarbonylalkyl;
  • Ar is substituted aryl or substituted heteroaryl having at least one substituent which independently is hydrogen, alkyl, alkenyl, alkenoxy, alkynyl, aldehyde, alkanoyl, alkoxy, amido, amino, aryl, aryloxy, carboxy, cyano, cycloalkyl, ether, ester, halogen, heterocyclyl, hydroxy, ketone, nitro, oxo, perfluoroalkyl, sulfonyl, sulfonate, thio, or other carbonyl-containing groups.
  • R6 is not an unsubstituted heterocyclylalkyl of the following structures:
  • Formula VIII [00219] The compound of Formula VIII, wherein m is 0, 1 or 2; X is H, cycloalkyl or phenyl, which is unsubstituted or substituted with one or more substituents which are lower alkyl, hydroxy or halogen; n is 0 or 1 ; and Y is phenyl, furanyl, indole or pyrrole, which all may be substituted with one or more substituents which are independently lower alkyl, lower alkoxy, halogen, (3,5-dimethylphenoxy)propoxy, or phenyl, wherein phenyl may be further substituted with one or more halogen atoms, nitro, amino or carboxyl groups. [00220] One exemplary compound of Formula VIII is
  • the present invention provides a 3a,4,5,6- tetrahydro-pyrrolol,2-b]-isothiazole , and its pharmaceutically acceptable salts, wherein the sulphur is in the form of a dioxide which is a compound of Formula IX., which is useful in the methods of the present invention.
  • R 3 is hydrogen, COOR 6 , or aminocarbonyl, or optionally substituted alkyl, alkenyl, alkynyl, aralkyl, alkoxy, cycloalkyloxy, aryloxy, or heterocycyloxy,
  • R 5 and R 6 independently of each other are alkyl, alkenyl, alkynyl, cycloalkyl, aryl or heterocyclyl,
  • the compound of Formula IX is:
  • each of a b and ⁇ ⁇ independently, is either a single bond or a double bond;
  • Rj is """"H, "C M alkyl or ⁇ - OR n
  • R 0 is H, C 1 ⁇ alkyl optionally substituted by OH or C M alkoxy, C 2 ⁇ alkenyl or aryl-C M alkyl;
  • R 2 is OH; — O— CO— R 5 ,
  • R 4 is H or ORi 9 wherein R 19 is C 1 ⁇ alkyl, hydroxy-C, ⁇ alkyl, C 1A alkoxy-C 1-6 alkyl, aryl-C ⁇ alkyl or C M alkoxycarbonyl-Ci. 4 alkyl;
  • each OfR 9 and Ri 0 independently is H or C ⁇ alkyl, or R 9 and Ri 0 form together with the nitrogen to which they are bound, a heteroaryl group; [00241] R 3 is a lactam of formula X-a:
  • R 30 is Ci -8 alkyl, C 3-7 cycloalkyl, aryl, C 3-7 c ycloalkyl-C ⁇ alkyl, alkyl, heteroaryl, or heteroaryl-C M ;
  • the compound of Formula X is one of the following compounds: [002461 v.
  • a family of hydantoin-based inhibitors can also be used as antagonists. See Kelly, T.
  • a compound according to formula XI is provided for use in the methods of the invention.
  • the compound of Formula XI is:
  • the term "subject * ' as used herein includes animals, in particular humans as well as other mammals.
  • the term "treating" and its grammatical equivalents as used herein includes achieving a therapeutic benefit and/or a prophylactic benefit.
  • therapeutic benefit is meant eradication or amelioration of the underlying disorder being treated.
  • a therapeutic benefit is achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the subject, notwithstanding that the subject may still be afflicted with the underlying disorder.
  • compositions may be administered to a subject at risk of developing a particular disease, or to a subject reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease may not have been made.
  • the compositions may be administered to a subject to prevent progression of physiological symptoms or of the underlying disorder.
  • methods are provided to administer a therapeutic agent to a subject to treat diabetic retinopathy.
  • the therapeutic agent is a LFA-I antagonist.
  • the LFA-I antagonist is a directly competitive antagonist of LFA-I.
  • the LFA-I antagonist is a competitive antagonist of LFA-I.
  • the LFA-I antagonist is an allosteric antagonist of LFA-I.
  • the LFA-I antagonist can modulate inflammation mediated by leukocytes.
  • Another embodiment of the invention treats a subject by administering a therapeutically effective amount of an antagonist of LFA-I to modulate inflammation associated with ocular inflammation.
  • An embodiment of the invention treats a subject with symptoms of diabetic retinopathy by administering a therapeutically effective amount of a LFA-I antagonist.
  • methods are provided to treat a subject with symptoms of Type II diabetes by administering a therapeutically effective amount of a LFA-I antagonist.
  • methods are provided to treat a subject with symptoms of Type I diabetes by administering a therapeutically effective amount of a LFA-I antagonist.
  • methods are provided to treat a subject by administering a therapeutically effective amount of a LFA-I antagonist to decrease retinal edema in an eye of the subject.
  • methods are provided to treat a subject by administering a therapeutically effect amount of a LFA-I antagonist to decrease macular edema.
  • methods are provided to treat a subject by administering a therapeutically effective amount of a LFA-I antagonist to decrease basement membrane thickening in an eye of the subject.
  • methods are provided to treat a subject by administering a therapeutically effective amount of a LFA-I antagonist to decrease retinal neovascularization in an eye of the subject.
  • methods are provided to treat a subject by administering a therapeutically effective amount of a LFA-I antagonist to retard the loss of vision due to diabetic retinopathy.
  • methods are provided to treat a subject by administering a therapeutically effective amount of a
  • methods are provided to slow proliferative damage to a retina in an eye of a subject suffering from diabetic retinopathy, by administering a therapeutically effective amount of a LFA-I antagonist.
  • methods are provided to reduce or prevent adhesion of leukocytes to capillary epithelial cells in an eye of a subject in need thereof, by administering a therapeutically effective amount of a LFA-I antagonist.
  • methods are provided to reduce or prevent damage from ischemic reperfusion in an eye of a subject in need thereof, by administering a therapeutically effective amount of a LFA-I antagonist.
  • methods which administer to a subject in need of treatment a therapeutically effective amount of a LFA-I antagonist which is a compound of Formulas VII, VIII, IX, X or XI.
  • a LFA-I antagonist which is a compound of Formulas VII, VIII, IX, X or XI.
  • vitrectomy procedures may be utilized.
  • Dexamethansone, a glucocorticoid steroid has been shown to be useful in reducing post-operative inflammation which can be enhanced in diabetic subjects relative to non-diabetic subjects.
  • methods are provided to reduce postoperative inflammation in diabetic subjects undergoing vitrectomy procedures by administering an LFA-I antagonist to the subject in need thereof.
  • an LFA-I antagonist of the invention may be administered to a subject prior to a vitrectomy procedure to prophylactically reduce post-operative inflammation.
  • photodynamic therapy may be utilized to correct occlusion or leakiness, and may cause excessive inflammation in a diabetic subject.
  • methods are provided to reduce postoperative inflammation in diabetic subjects undergoing laser photocoagulation therapeutic procedures by administering an LFA-I antagonist to the subject in need thereof.
  • an LFA-I antagonist of the invention may be administered to a subject prior to a laser photocoagulation therapy procedure to prophylactically reduce post-operative inflammation.
  • anterior chamber complications include pigment dispersion with precipitates on the surface of the newly implanted intraocular lens (IOL), fibrinous exudates or membrane formation (from inflammation) in the anterior chamber.
  • methods are provided to reduce anterior or posterior segment complications following cataract surgery in an eye of a subject with DME, by administering a LFA-I antagonist to a subject in need thereof.
  • methods are provided to prophylactically administer a LFA-I antagonist to a subject with DME who is at higher risk of developing cataracts compared to a healthy subject, thereby reducing or preventing developing cataracts.
  • the methods generally involve the administration of one or more drugs for the treatment of diabetic retinopathy where the drug is delivered to or is distributed subsequent to delivery to the retina or intraocular region of the eye.
  • Combinations of agents can be used to treat diabetic retinopathy or to modulate the side-effects of one or more agents in the combination. Since the pathological events in this disease state are marked by a combination of impaired autoregulation, apoptosis, ischemia, reperfused tissue, neovascularization, and inflammatory stimuli, it may be desirable to administer the LFA-I antagonists of the invention in combination with other therapeutic agents to additionally or synergistically intervene.
  • the second therapeutic agent is an antioxidant, antiinflammatory agent, antimicrobial, antiangiogenic agent, and/or anti-apoptotic agent.
  • an additional therapeutic agent in addition to administering a compound which directly competes for binding to LFA-I, an additional therapeutic agent may be administered which is an allosteric, but not a directly competitive, anatagonist of LFA-I as discussed above, potentially resulting in synergistic efficacy.
  • An example of such allosteric antagonist is the class of hydantoin inhibitors of LFA-I.
  • Other examples of allosteric antagonists include compounds of Formula VII, VIII, IX 1 X, or XI.
  • Another class of therapeutic agents which my be useful to administer in combination with, prior to , after or concomitantly with the LFA-I antagonists of the invention is an anti- adhesion therapeutic antibody or antibody fragment.
  • VEGF inhibitor may be of use in the compositions of the invention, which include, but are not limited to 1) neutralizing monoclonal antibodies against VEGF or its receptor, 2) small molecule tyrosine kinase inhibitors of VEGF receptors, 3) soluble VEGF receptors which act as decoy receptors for VEGF, 4) ribozymes which specifically target VEGF, and 5) siRNA which specifically targets VEGF signalling proteins.
  • antibodies which are active against VEGF are, for example, e.g., Lucentis (ranibizumab), and Avastin (bevacizumab).
  • An example of an oligonucleotide drug is, e.g., Macugen (pegaptanib sodium injection).
  • Small molecule tyrosine kinase inhibitors include, for example, pazopanib, sorafenib, sutent, and the like.
  • the anti-inflammatory agents can be chosen from corticosteroid related drugs including but not limited to dexamethasone, fluoromethalone, medrysone, betamethasone, triamcinolone, triamcinolone acetonide, prednisone, prednisolone, hydrocortisone, rimexolone, and pharmaceutically acceptable salts thereof, prednicarbate, deflazacort, halomethasone, tixocortol, prednylidene , prednival, paramethasone, methylprednisolone, meprednisone, mazipredone, isoflupredone, halopredone acetate, halcinonide, formocortal, flurandrenolide, fluprednisolone, fluprednidine acetate, fluperolone acetate, fluocortolone, fluocortin butyl, fluocinonide, fluocinolone acet
  • the antiinflammatory agents can be chosen from the group of NSAIDs including but not limited to acetaminophen, acemetacin, aceclofenac, alminoprofen, amfenac, bendazac, benoxaprofen, bromfenac, bucloxic acid, butibufen, carprofen, celecoxib, cinmetacin, clopirac, diclofenac, etodolac, etoricoxib, felbinac, fenclozic acid, fenbufen, fenoprofen, fentiazac, flunoxaprofen, flurbiprofen, ibufenac, ibuprofen, indomethacin, isofezolac, isoxicam, isoxepac, indoprofen, ketoprofen, lonazolac, loxoprofen, mefenamic acid, meclofenamic acid,
  • Another group of therapeutic agents which may be useful to administer in combination, prior to, after, or concomitantly with the LFA-I antagonists of the invention is the group of drugs which are known to inhibit retinopathy by inhibiting NFK ⁇ .
  • Some of these classes of therapeutics include PARP inhibitors, benfotiamine or other agents which intervene in blockade of AGEs (advanced glycation endproducts), aldose reductase inhibitors, iNOS inhibitors, FasL inhibitors, or angiopoeitin-1.
  • Oxidative stress may be induced in cells with impaired autoregulatory and ischemic processes induced by DR.
  • anti-oxidants may be useful to administer in combination, prior to, after, or concomitantly with the LFA-I antagonists of the invention.
  • suitable anti-oxidants useful in the methods of the invention include, but are not limited to, ascorbic acid, tocopherols, tocotrienols, carotinoids, glutathione, alpha-lipoic acid, ubiquinols, bioflavonoids, carnitine, and superoxide dismutase mimetics, such as, for example, 2,2,6,6-tetramethyl- 1-piperidinyloxy (TEMPO), DOXYL, PROXYL nitroxide compounds; 4-hydroxy-2,2,6,6-tetramethyl-l- piperidinyloxy (Tempol), M-40401, M-40403, M-40407, M-40419,M-40484, M-40587, M-40588, and the like.
  • TEMPO 2,2,6,6-tetramethyl- 1-piperidinyloxy
  • the LFA-IACAM binding event is downstream of complement activation of ICAM upregulation in tissue and on vascular/capilary epithelial cells.
  • Administration of both a complement inhibitor and LFA-I antagonist may permit more complete modulation of LFA-I expressing leukocytes.
  • a complement inhibitor is Eculizumab.
  • Other complement inhibitors include, but are not limited to U.S. Patent Nos. 7166568, 6319897, 5843884, 5135916, and 5624837.
  • Another class of therapeutic agents which may be useful to administer in combination, prior to, after, or concomitantly with the LFA-I antagonists of the invention are medications used in the management of glaucoma in patients with background DM, which includes primary, open angle, angle-closure as well as neovascular glaucoma.
  • Some of the therapeutic agents used for glaucoma include but are not limited to prostaglandin analogs such as, for example, latanoprost , bimatoprost, and travaprost; topical beta- adrenergic receptor antagonists such as, for example, timolol, levobunolol, and betaxolol; alpha 2- adrenergic agonist such as, for example, brimonidine; sympathomimetics such as for example, epinephrine or dipivif ⁇ n; miotic agents, such as, for example, pilocarpine; carbonic anhydrase inhibitors, such as , for example, dorzolamide, brinzolamide, and acetozolamide; or physostigmine.
  • prostaglandin analogs such as, for example, latanoprost , bimatoprost, and travaprost
  • topical beta- adrenergic receptor antagonists such as
  • antimicrobial agents include, but are not limited to, penicillins, such as, for example, amoxicillin, ampicillin, azlocillin, carbenicillin, cloxacillin, dicloxacillin, flucloxacillin, mezlocillin, nafcillin, penicillin, piperacillin, ticarcillin, and the like; beta-lactamase inhibitors; carbapenems, such as, for example, ertapenem, imipenem, meropenem, and the like; cephalosporins, such as, for example, cefaclor, cefamandole, cefoxitin, cefprozil, cefuroxime, cefixime, cefdinir, cefditoren, cefoperazone, cefotaxime,
  • Examples of other therapeutic agents which may be useful to administer in combination, prior to, after, or concomitantly with the LFA-I antagonists of the invention are, include, but are not limited to: (a) anti-diabetic agents such as insulin and insulin mimetics, sulfonylureas (e.g., glyburide, meglinatide), biguanides, e.g., metformin
  • GlucophageTM .alpha.-glucosidase inhibitors (acarbose), insulin sensitizers, e.g., thiazolidinone compounds, rosiglitazone (AvandiaTM), troglitazone (RezulinTM), ciglitazone, pioglitazone (ActosTM) and englitazone;
  • cholesterol lowering agents such as HMG-CoA reductase inhibitors (e.g., lovastatin, simvastatin, pravastatin, fiuvastatin, atorvastatin and other statins), bile acid sequestrants (e.g., cholestyramine and colestipol) , vitamin B 3 (also known as nicotinic acid, or niacin), vitamin B ⁇ (pyridoxine), vitamin B ⁇ (cyanocobalamin), fabric acid derivatives (e.g., gemfibrozil, clofibrate,
  • the LFA-I antagonist is present in an amount sufficient to exert a therapeutic effect to reduce symptoms of diabetic retinopathy by an average of at least about 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, more than 90%, or substantially eliminate symptoms of diabetic retinopathy.
  • the LFA-I antagonist is present in an amount sufficient to reduce retinal degeneration in a subject by an average of at least about 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, more than 90%, or substantially eliminate retinal degeneration.
  • the LFA-I antagonist is present in an amount sufficient to decrease retinal edema in a treated eye of a subject by an average of at least about 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, more than 90%, or substantially eliminate retinal edema.
  • the LFA-I antagonist is present in an amount sufficient to decrease basement membrane thickening in a treated eye of a subject by an average of at least about 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, more than 90%, or substantially eliminate basement membrane thickening.
  • the LFA-I antagonist is present in an amount sufficient to decrease retinal neovascularization in a treated eye of a subject by an average of at least about 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, more than 90%, or substantially eliminate retinal neovascularization.
  • the LFA-I antagonist is present in an amount sufficient to decrease fibrovascular growth over a retina in a treated eye of a subject by an average of at least about 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, more than 90%, or substantially eliminate fibrovascular growth over the retina.
  • the LFA-I antagonist is present in an amount sufficient to retard loss of vision in a treated eye of a subject by an average of at least about 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, more than 90%, or substantially eliminate further loss of vision.
  • the LFA-I antagonist is present in an amount sufficient to limit non-proliferative damage to a retina of a subject by an average of at least about 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, more than 90%, or substantially eliminate the non-proliferative damage to the retina.
  • the LFA-I antagonist is present in an amount sufficient to slow proliferative damage to a retina of a subject by an average of at least about 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, more than 90%, or substantially eliminate further proliferative damage to the retina.
  • an effective amount of the LFA-I antagonist is a daily dose of about Ix 10- 11 , Ix 10- 10 , Ix 10- 9 , Ix 10 "8 , Ix 10- 7 , Ix 10 "6 , Ix 10 "5 , Ix lO "4 , Ix 10 3 , Ix W 2 , Ix 10 1 , 1, Ix 10 1 , Ix 10 2 grams.
  • Administration of the therapeutic agent may be by any suitable means.
  • the therapeutic agent is administered by oral administration.
  • the therapeutic agent is administered by transdermal administration.
  • the therapeutic agent is administered by instillation.
  • the therapeutic agent is administered by injection.
  • the therapeutic agent is administered by slow release intravitreal injection.
  • the therapeutic agent is administered by slow release intraocular implantation.
  • the therapeutic agent is administered by periocular implantation.
  • the therapeutic agent is administered topically. . In some embodiments, the therapeutic agent is administered topically, via an eye drop. If combinations of agents are administered as separate compositions, they may be administered by the same route or by different routes.
  • combinations of agents are administered in a single composition, they may be administered by any suitable route. In some embodiments, combinations of agents are administered as a single composition by oral administration. In some embodiments, combinations of agents are administered as a single composition by transdermal administration. In some embodiments, the combinations of agent are administered as a single composition by injection. In some embodiments, the combinations of agent are administered as a single composition topically.
  • diagnostic procedures will be employed to identify a subject in need of treatment by the method of the invention.
  • An exemplary list of procedures that may be used to diagnose symptoms of diabetic retinopathy includes, e.g., for example, complete ophthalmic examination (which may include Amsler grid examination and slit lamp examination), fundus photography, fluorescein angiography, optical coherence tomography, non-myriadic photography, and beta scan ultrasound, conventional ocular exam, optical coherence tomography, beta scan ultrasound alone, complete ophthalmic examination with fundus photography and fluorescein angiography.
  • the antagonist of the method of the invention may be an antibody, fragment of an antibody, peptide or small molecule.
  • the LFA-I antagonist used is a peptide which is not an antibody.
  • the, LFA-I antagonist used is a small molecule.
  • treating or preventing the symptoms of diabetic retinopathy by using LFA-I antagonists requires chronic therapy; therefore, small molecule inhibitors of the LFA-I /ICAM-I interaction may be utilized as they have the potential for local administration as ocular drops with a lowered cost of goods. Similarly oral administration offers advantages in lowered cost of goods.
  • Implantable devices which may be biodegradable or bioabsorbable or biodegradable slow release or sustained release formulations implanted or injected into the eye or near the eye in periocular tissue are used for chronic therapy.
  • Another embodiment is a method of treating the symptoms of diabetic retinopathy using therapeutic agents which are suitable for formulation and administration as ocular therapeutics.
  • a cream formulation of the compounds of the invention may be useful in the local delivery of a LFA-I antagonist to the skin.
  • Compounds useful in this regard include LFA-I antagonists and their pro-drugs which are transformed into the active drug once within the skin.
  • a skin cream applied to the outer surface of the eyelids thus delivering a LFA-I antagonist across the eyelid to the inner lining of the eyelid and the intervening conjunctival tissue and accessory lacrimal glands and appear in tear and thus be absorbed into the eye.
  • This form of delivery may be desirable in treating LFA-I mediated inflammation of the eye, particularly in the treatment of diabetic retinopathy. in. Administration.
  • the method of the present invention may draw upon many suitable modes of administration to deliver the LFA-I antagonist of the methods described herein. Such delivery to affected regions of the body may be achieved either via local or systemic administration. Suitable formulations and additional carriers are described in Remington "The Science and Practice of Pharmacy” (20 th Ed., Lippincott Williams & Wilkins, Baltimore MD), the teachings of which are incorporated by reference in their entirety herein. [00293]
  • the invention provides a pharmaceutical composition for administration to a subject containing: (i) an effective amount of a therapeutic agent; and (ii) a pharmaceutical excipient suitable for oral administration.
  • the composition further contains: (iii) an effective amount of a second therapeutic agent.
  • a pharmaceutical composition of the invention can comprise any of the molecules disclosed herein.
  • the pharmaceutical composition of the invention is preferably delivered to the retina, intraocular space, ocular surface, interconnecting innervation, conjunctiva, lacrimal glands, or meibomian glands. It is envisioned that effective treatment can encompass administering therapeutic agents of the present invention via oral administration, topical administration, via injection, intranasally, rectally, transdermally, via an impregnated or coated device such as an ocular insert or implant, or iontophoretically, amongst other routes of administration.
  • the pharmaceutical composition can be injected intraocularly, periocularly, intramuscularly, intra-arterially, subcutaneously, or intravenously.
  • a pump mechanism may be employed to administer the pharmaceutical composition over a preselected period.
  • injections may be made periocularly, intraocularly, intravitreally, subconjunctively, retrobulbarly, into the sclera, or intercamerally.
  • systemic delivery is preferred.
  • the compounds of the invention can be formulated for and administered orally.
  • the composition of the invention may be administered intranasally, transdermally, or via some forms of oral administration, e. g. with use of a mouthwash or lozenge incorporating a compound of the invention that is poorly absorbed from the G.I.
  • iontophoretic or topical administration may be used.
  • the pharmaceutical compositions of the present invention may be administered to the ocular surface via a pump-catheter system, or released from within a continuous or selective release device such as, e.g., membranes such as, but not limited to, those employed in the OcusertTM System (Alza Corp, Palo Alto, CA).
  • a continuous or selective release device such as, e.g., membranes such as, but not limited to, those employed in the OcusertTM System (Alza Corp, Palo Alto, CA).
  • the pharmaceutical compositions can be incorporated within, carried by or attached to contact lenses which are then worn by the subject.
  • the pharmaceutical compositions can be sprayed onto ocular surface.
  • the typical daily dose ranges are, e.g. about lxl ⁇ '8 g to 5.0g, or about lxl ⁇ "8 g to 2.5g, or about lxl ⁇ ⁇ 8 g to l.OOg, or about lxl ⁇ "8 g to 0.5g, or about lxl ⁇ "8 g to 0.25g, or about 1x10 " 8 g to O.lg, or about lxl ⁇ "8 g to 0.05g, or about lxl ⁇ "8 g to 0.025g, or about lxl ⁇ '8 g to Ix 10 "2 g, or about lxl ⁇ "8 g to 5x 10 "3 g, or about lxl ⁇ "8 g to 2.5x 10 "3 g, or about lxl ⁇ '8 g to Ix 10 "3 g, or about lxl ⁇ "8 g to 5x 10
  • an eye drop formulation of the invention release sufficient therapeutic agent intraocularly or periocularly to achieve a level of LFA-I antagonist in the retina of at least about 1OnM, about 5OnM, about 10OnM, about 15OnM, about 20OnM, about 25OnM, about 300 nM, about 35OnM, about 50OnM, about 60OnM, about 70OnM, about 80OnM, about 900 nM, about ImM, about 2mM, about 3mM, about 5mM, about 6mM, about7mM, about 8mM, about 9mM, about 1OmM, about 15mM, about 2OmM or about 25 mM from dose to dose.
  • the sustained release formulation and/or implantations release sufficient therapeutic agent intraocularly or periocularly to sustain a level of LFA-I antagonist of at least about 1OnM, about 5OnM, about 10OnM, about 15OnM, about 20OnM, about 25OnM, about 300 nM, about 35OnM, about 50OnM, about 60OnM, about 70OnM, about 80OnM, about 900 nM, about ImM, about 2mM, about 3mM, about 5mM, about 6mM, about7mM, about 8mM, about 9mM, about 1OmM, about 15mM, about 2OmM or about 25 mM across 6 months. IV. Formulations.
  • any of the forms of LFA-I may also be milled to provide more suitable properties for formulation. Milling may provide smaller particle size with greater surface area exposure, which can provide faster solubilization in- vivo or during formulation. Alternatively, milling to a smaller particle size may provide the capacity to pass through biological barriers, such as the skin or gut wall, directly, without initial solubilization, permitting use as a solid in the formulation, which may provide additional benefits of temperature stability, shelf life, ease of transport, and ease of use by the subject.
  • anti- wrinkle and anti-skin atrophy agents are retinoic acid and its derivatives, retinol, retinyl esters, salicylic acid and its derivatives, sulfur-containing D and L amino acids except cysteine, alpha-hydroxy acids (e.g., glycolic acid and lactic acid), phytic acid, lipoic acid and lysophosphatidic acid.
  • the formulations may also contain irritation-mitigating additives to minimize or eliminate the possibility of skin irritation or skin damage resulting from the other components of the composition.
  • the preservative preferably benzalkonium chloride
  • the preservative may be employed at a level of from 0.001% to less than 0.01%, e.g. from 0.001% to 0.008%, preferably about 0.005% by weight. It has been found that a concentration of benzalkonium chloride of 0.005% may be sufficient to preserve the compositions of the present invention from microbial attack.
  • One embodiment of the invention has a formulation of about 1.0 to 10.0 W/V % of the compounds of the invention.
  • One embodiment of the invention has a formulation of about 0.01 to 10.0 W/V % of the compounds of the invention.
  • One embodiment of the invention has a formulation of about 5.0 to 10.0 W/V % of the compounds of the invention.
  • These formulations may be applied or sprayed several times a day, preferably one to six times, more preferably one to four times, and most preferably once a day.
  • the compounding ratio of each ingredient may be suitably increased or decreased based on the degree of inflammations or infections.
  • the formulations of the invention can further include other pharmacological active ingredients as far as they do not contradict the purpose of the present invention.
  • their respective contents may be suitably increased or decreased in consideration of their effects and safety.
  • Example 2 LFA- 1/IC AM-I and LFA-1/Small Molecule Enzyme-Linked Immunosorbent Assays (ELISAs).
  • ELISAs LFA- 1/IC AM-I and LFA-1/Small Molecule Enzyme-Linked Immunosorbent Assays.
  • A Antagonist Competition: Small molecules and sICAM-1 were assayed for the ability to disrupt binding of ICAM-I-Ig or a fluorescein-labeled small molecule antagonist, compound 2B, to LFA-I in a competitive format. Compound 2B is similar to compound 1 , but with a longer linker between the small molecule and fluorescein to maximize the binding of the anti-fluorescein detection antibody.
  • 96-well plates were coated with 5 ⁇ g/ml (33.3 nM) mouse anti-human B2 integrin (a non-function blocking antibody) in phosphate-buffered saline (PBS) overnight at 4
  • the EC 50 values generated in the presence and absence of antagonist were analyzed by Schild regression .
  • the molar ratio of compound 5 to LFA- 1 was 3: 1.
  • a 96- well plate precoated with 1 % BSA was used for the incubation.
  • excess compound 5 was rapidly removed by gel filtration with a G-25 microspin column in a 96-well format equilibrated with the same buffer.
  • the LFA-I /compound 5 complex was crosslinked by exposure to a high-pressure mercury- vapor lamp (450 watts, Ace glass, Vineland, NJ). During irradiation, samples were cooled on ice and protected by a 5-mm thick plate of borosilicate glass to minimize protein degradation. Residual unlinked compound 5 was removed by gel filtration
  • Example 4 Generation of the ⁇ L Construct Lacking the I domain.
  • the construct used, pLFA.huID. ⁇ p contains the sequence of the ⁇ L gene from the Narl restriction site 5' of the I domain to the second PflMl restriction site 3' of the I domain in which the first PfIMl restriction site 3' of the I domain was abolished (Edwards et al. 1995).
  • the forward primer the forward primer
  • Example 5 Binding of LFA-I Lacking the I domain to ICAM-I or Compound 2B.
  • Example 6 Streptozotocin-Induced Rat Diabetic Retinopathy Model .
  • Example 7 Human T-CeIl Adhesion Assay.
  • the T-cell adhesion assay was performed using the human T-lymphoid cell line HuT 78 (ATCC TIB-161).
  • Goat anti-HuIgG(Fc) was diluted to 2 ⁇ g/ml in PBS and 96-well plates were coated with 50 ⁇ l/well at 37°C for 1 h. Plates were washed with PBS and blocked for 1 h at room temperature with 1% BSA in PBS.
  • 5 domain ICAM-Ig was diluted to 100 ng/ml in PBS and 50 ⁇ l/well was added to the plates O/N at 4°C.
  • HuT 78 cells were centrifuged at 100 g and the cell pellet was treated with 5 mM EDTA for ⁇ 5' at 37°C in a 5% CO 2 incubator. Cells were washed in 0.14 M NaCl, 0.02 M Hepes, 0.2% glucose and 0.1 mM MnCl 2 (assay buffer) and centrifuged. The cells were resuspended in assay buffer to 3.0X10 6 c/ml. Inhibitors were diluted in assay buffer to a 2X final concentration and pre-incubated with HuT78 cells for 30' at room temperature. 100 ⁇ l/well of cells and inhibitors were added to the plates and incubated at room temperature for 1 h.
  • HUT 78 cell adhesion to 5dICAM-Ig was measured using the p- nitrophenyl n-acetyl-. ⁇ -D-glucosaminide method of Landegren, U. (1984). J. Immunol. Methods 57, 379-388. The results are shown in Table 1.
  • the scale in the table represents EC 50 values as follows: * represents 3 ⁇ M or less, ** represents 300 nM or less, *** represents 100 nM or less, and **** represents 50 nM or less.
  • Example 8 In- Vitro Inhibition of Antigen Stimulated Release of Cytokines From Human Peripheral Blood Monocytes (PBMC).
  • PBMC Peripheral Blood Monocytes
  • a directly competitive LFA-I antagonist of the invention was evaluated for its ability to inhibit release of inflammatory cytokines, in human mononucleocytes (PBMC) stimulated with staphylococcal enterotoxin B (SEB).
  • PBMC human mononucleocytes
  • SEB staphylococcal enterotoxin B
  • Stock solutions of antagonist, Rebamipide (a mucosal protective agent), and Cyclosporin A (CsA) were prepared in culture media and dilutions were prepared by addition of culture media to achieve the desired concentration.
  • Negative controls were prepared without SEB stimulation. SEB stimulation with vehicle (0.25% DMSO/media) was used as the positive control.
  • the antagonist demonstrated potent inhibition of the release of inflammatory cytokines, particularly the T- cell regulating cytokines, IL-2 and IL-4, with increasing dose.
  • the results are shown in Tables 2, 3, and 4 and graphically represented in Figure 11.
  • the pattern of cytokine release inhibited by more than 50% with the directly competitive LFA-I antagonist is similar to that seen in comparison with CsA.
  • the exceptions to this similarity, IL- 3, 11-6, and IL-12p40, have not been shown to be important to T-cell mediated inflammation.
  • Example 9 Formulations of an LFA-I Antagonist.
  • a directly competitive LFA-I antagonist of the invention was formulated in several compositions for administration as gels, lotions, ointments, and solutions, for administration by varying routes, including but not limited to topical, via instillation, aerosol, transdermal patch, via insert, or oral administration.
  • Example 10 In- Vitro pPercutaneous Absorption of a Directly Competitive Antagonist of LFA-I of the Invention Following Topical Application.
  • Formulation 9 which contained 99% DMSO, were below the limits of quantitation, which was 0.54ng/ml (which is equivalent to 0.013% of the applied dose).
  • Formulation 9 in contrast, provided 1.4% of the applied dose, permeating through all the layers of the skin tissue over the exposure period of 24 hours.
  • Epidermal deposition of LFA-I Antagonist over the 24 hour exposure period was very high and consistent with a large percentage of the applied dose being retained in the upper layers of the epidermis. The levels reported in Table 10 were obtained from small volume samples, which could not be re-assayed, and thus are considered underestimates of the amount of drug present in the epidermis.
  • This assay is an in vitro model of lymphocyte proliferation resulting from activation, induced by engagement of the T-cell receptor and LFA-I , upon interaction with antigen presenting cells (Springer, Nature 346:

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Obesity (AREA)
PCT/US2008/011878 2007-10-19 2008-10-17 Compositions and methods for treatment of diabetic retinopathy Ceased WO2009054914A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP20189143.9A EP3797775A1 (en) 2007-10-19 2008-10-17 Compositions and methods for treatment of diabetic retinopathy
EP16204718.7A EP3167886B1 (en) 2007-10-19 2008-10-17 Compositions and methods for treatment of macular edema
MX2010004281A MX2010004281A (es) 2007-10-19 2008-10-17 Composiciones y metodos para el tratamiento de la retinopatia diabetica.
CA2702984A CA2702984C (en) 2007-10-19 2008-10-17 Compositions and methods for treatment of diabetic retinopathy
CN200880117716A CN101873797A (zh) 2007-10-19 2008-10-17 用于治疗糖尿病性视网膜病的组合物和方法
ES08842113.6T ES2630406T3 (es) 2007-10-19 2008-10-17 Composición y procedimientos para el tratamiento de la retinopatía diabética
JP2010529955A JP5808037B2 (ja) 2007-10-19 2008-10-17 糖尿病性網膜症の治療のための組成物及び方法
EP08842113.6A EP2209371B1 (en) 2007-10-19 2008-10-17 Compositions and methods for treatment of diabetic retinopathy
AU2008317473A AU2008317473B2 (en) 2007-10-19 2008-10-17 Compositions and methods for treatment of diabetic retinopathy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99957107P 2007-10-19 2007-10-19
US60/999,571 2007-10-19

Publications (1)

Publication Number Publication Date
WO2009054914A1 true WO2009054914A1 (en) 2009-04-30

Family

ID=40579823

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/011878 Ceased WO2009054914A1 (en) 2007-10-19 2008-10-17 Compositions and methods for treatment of diabetic retinopathy

Country Status (9)

Country Link
US (3) US20090155176A1 (cg-RX-API-DMAC10.html)
EP (3) EP3167886B1 (cg-RX-API-DMAC10.html)
JP (2) JP5808037B2 (cg-RX-API-DMAC10.html)
CN (1) CN101873797A (cg-RX-API-DMAC10.html)
AU (1) AU2008317473B2 (cg-RX-API-DMAC10.html)
CA (3) CA2702984C (cg-RX-API-DMAC10.html)
ES (2) ES2830024T3 (cg-RX-API-DMAC10.html)
MX (1) MX2010004281A (cg-RX-API-DMAC10.html)
WO (1) WO2009054914A1 (cg-RX-API-DMAC10.html)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8598156B2 (en) 2010-03-25 2013-12-03 Glaxosmithkline Llc Chemical compounds
WO2018167113A1 (en) * 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag New bicyclic compounds as atx inhibitors
US10633384B2 (en) 2012-06-13 2020-04-28 Hoffmann-La Roche Inc. Diazaspirocycloalkane and azaspirocycloalkane
US10640472B2 (en) 2015-09-04 2020-05-05 Hoffman-La Roche Inc. Phenoxymethyl derivatives
US10647719B2 (en) 2015-09-24 2020-05-12 Hoffmann-La Roche Inc. Bicyclic compounds as dual ATX/CA inhibitors
US10654857B2 (en) 2014-03-26 2020-05-19 Hoffman-La Roche Inc. Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors
US10669268B2 (en) 2012-09-25 2020-06-02 Hoffmann-La Roche Inc. Bicyclic derivatives
US10669285B2 (en) 2014-03-26 2020-06-02 Hoffmann-La Roche Inc. Condensed [1,4] diazepine compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors
US10689371B2 (en) 2018-04-18 2020-06-23 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US10738053B2 (en) 2015-09-24 2020-08-11 Hoffmann-La Roche Inc. Bicyclic compounds as dual ATX/CA inhibitors
US10787459B2 (en) 2015-09-24 2020-09-29 Hoffmann-La Roche Inc. Bicyclic compounds as ATX inhibitors
US10800786B2 (en) 2015-09-24 2020-10-13 Hoffman-La Roche Inc. Bicyclic compounds as ATX inhibitors
US10849881B2 (en) 2013-11-26 2020-12-01 Hoffmann-La Roche Inc. Octahydro-cyclobuta[1,2-c;3,4-c′]dipyrrol-2-yl
US10913745B2 (en) 2013-03-12 2021-02-09 Hoffmann-La Roche Inc. Octahydro-pyrrolo[3,4-c]-pyrrole derivatives and analogs thereof as autotaxin inhibitors
US10960087B2 (en) 2007-10-19 2021-03-30 Novartis Ag Compositions and methods for treatment of diabetic retinopathy
US11059794B2 (en) 2017-03-16 2021-07-13 Hoffmann-La Roche Inc. Heterocyclic compounds useful as dual ATX/CA inhibitors
US11426412B2 (en) 2017-10-18 2022-08-30 Jubilant Epipad LLC Imidazo-pyridine compounds as PAD inhibitors
US11459338B2 (en) 2017-11-24 2022-10-04 Jubilant Episcribe Llc Heterocyclic compounds as PRMT5 inhibitors
US11529341B2 (en) 2018-03-13 2022-12-20 Jubilant Prodel LLC Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation
US11629135B2 (en) 2017-11-06 2023-04-18 Jubilant Prodell Llc Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
US11833156B2 (en) 2017-09-22 2023-12-05 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
US11919912B2 (en) 2018-05-21 2024-03-05 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US12516040B2 (en) 2019-07-24 2026-01-06 Constellation Pharmaceuticals, Inc. Crystalline forms of 7-chloro-2-(4-3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004287875B2 (en) 2003-11-05 2011-06-02 Bausch + Lomb Ireland Limited Modulators of cellular adhesion
SI1881823T1 (sl) * 2005-05-17 2015-04-30 Sarcode Bioscience Inc. Sestavki in postopki za zdravljenje bolezni oäśesa
EP3632444A3 (en) * 2008-04-15 2020-08-26 SARcode Bioscience Inc. Topical lfa-1 antagonists for use in localized treatment of immune related disorders
WO2009139817A2 (en) * 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
CN102065694A (zh) * 2008-04-15 2011-05-18 萨可德公司 用于局部治疗免疫相关疾病的雾化的lfa-1拮抗剂
EP2276508A4 (en) * 2008-04-15 2011-12-28 Sarcode Bioscience Inc ADMINISTRATION OF LFA-1 ANTAGONISTS TO THE GASTROINTESTINAL SYSTEM
US8378105B2 (en) * 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
ES2752008T3 (es) * 2009-10-30 2020-04-02 Intratus Inc Métodos y composiciones para la liberación sostenida de fármacos
US20110189174A1 (en) * 2010-02-01 2011-08-04 Afshin Shafiee Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization
TW201206908A (en) * 2010-05-05 2012-02-16 Glaxo Wellcome Mfg Pte Ltd Pharmaceutical compositions and methods of making same
HK1204988A1 (en) * 2012-02-22 2015-12-11 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
CA2875053C (en) 2012-06-05 2020-07-14 Olatec Industries Llc Pharmaceutical composition for treating inflammation and pain
EP2877465A4 (en) 2012-07-25 2016-05-11 Sarcode Bioscience Inc LFA-1 HEMMER AND POLYMORPH THEREOF
JP6272604B2 (ja) * 2013-12-27 2018-01-31 日本サプリメント株式会社 糖取り込み促進剤
WO2016159351A1 (ja) * 2015-04-03 2016-10-06 参天製薬株式会社 涙腺ドラッグデリバリーシステム
KR102554417B1 (ko) 2018-06-18 2023-07-11 삼성전자주식회사 이미지 센서
EP3990433B1 (en) 2019-06-25 2026-05-20 Translatum Medicus Inc. PROCESSES FOR THE MANUFACTURE OF 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES
MX2022015327A (es) * 2020-06-05 2023-02-22 Occurx Pty Ltd Compuestos y metodos para el tratamiento de trastornos oculares.
CN116635032A (zh) * 2020-10-21 2023-08-22 阿祖拉眼科有限公司 用于治疗眼部病症的化合物和方法
EP4589369A4 (en) * 2022-09-15 2026-08-12 Nof Corp CONTACT LENS SOLUTION
WO2026052060A1 (zh) * 2024-09-06 2026-03-12 上海翊石医药科技有限公司 一类苯甲酰基甘氨酸衍生物及其制备方法和应用

Citations (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5135916A (en) 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
US5624837A (en) 1994-03-03 1997-04-29 Alexion Pharmaceuticals, Inc. Nucleic acid encoding chimeric complement inhibitor proteins
US5747035A (en) 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US5843885A (en) 1994-04-19 1998-12-01 The University Of Kansas ICAM-1/LFA-1 short-chain peptides and method of using same
US5843884A (en) 1995-11-15 1998-12-01 Oklahoma Medical Research Foundation C9 complement inhibitor
WO1999049856A2 (en) 1998-03-27 1999-10-07 Genentech, Inc. Antagonists for treatment of cd11/cd18 adhesion receptor mediated disorders
WO2000021920A1 (en) 1998-10-13 2000-04-20 F. Hoffmann-La Roche Ag Diaminopropionic acid derivatives
WO2001058853A1 (en) 2000-02-09 2001-08-16 F. Hoffmann-La Roche Ag Dehydroamino acids
US6319897B1 (en) 1996-03-13 2001-11-20 John D. Lambris Peptides which inhibit complement activation
WO2002059114A1 (en) 2000-11-28 2002-08-01 Genentech, Inc. Lfa-1 antagonist compounds
US20020132807A1 (en) 2000-06-29 2002-09-19 Wang Gary T. Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
US20020143035A1 (en) 2000-12-01 2002-10-03 Michele Launay Hydantoin compounds useful as anti-inflammatory agents
US20020156314A1 (en) 2000-06-29 2002-10-24 Link James T. Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents
US6488916B1 (en) 2001-03-21 2002-12-03 Schering-Plough Healthcare Products, Inc. Skin care compositions
US6630447B2 (en) 2000-01-14 2003-10-07 University Of New Mexico Peptide inhibitors of LFA-1/ICAM-1 interaction
US6630492B1 (en) 1997-08-28 2003-10-07 Novartis Ag Lymphocyte function antigen-1 antagonists
US20040009998A1 (en) 2001-10-01 2004-01-15 Dhar T. G. Murali Spiro-hydantoin compounds useful as anti-inflammatory agents
US20040028648A1 (en) 1998-12-30 2004-02-12 The Children's Medical Center Corporation Prevention and treatment of retinal ischemia and edema
US20040116518A1 (en) 1998-12-29 2004-06-17 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
US6818638B2 (en) 1999-02-16 2004-11-16 Novartis Ag Melvinolin derivatives
WO2005044817A1 (en) 2003-11-05 2005-05-19 Sunesis Pharmaceuticals, Inc. Modulators of cellular adhesion
US20050119279A1 (en) 2003-10-02 2005-06-02 Dhar T. G. M. Spiro-cyclic compounds useful as anti-inflammatory agents
US20060052434A1 (en) 2004-08-18 2006-03-09 Dhar T G M Pyrrolizine compounds useful as anti-inflammatory agents
US20060074099A1 (en) 2004-10-01 2006-04-06 Delmonte Albert J Crystalline forms and process for preparing spiro-hydantoin compounds
US20060142319A1 (en) 2004-12-14 2006-06-29 Bang-Chi Chen Pyridyl-substituted spiro-hydantoin crystalline forms and process
US20060148836A1 (en) 2004-12-14 2006-07-06 Dhar T G M Pyridyl-substituted spiro-hydantoin compounds and use thereof
US20060281739A1 (en) * 2005-05-17 2006-12-14 Thomas Gadek Compositions and methods for treatment of eye disorders
US7166568B1 (en) 1998-02-09 2007-01-23 Oklahoma Medical Research Foundation Compositions and methods to inhibit formation of the C5b-9 complex of complement
US20080108677A1 (en) 2004-08-30 2008-05-08 Karyon-Ctt Ltd Thioxothiazolidinone Compounds For Use As Pharmaceuticals
US20080234271A1 (en) 2004-04-28 2008-09-25 Icos Corporation Arylphenylamino- and Arylphenylether-Sulfide Derivatives, Useful For the Treatment of Inflammatory and Immune Diseases, and Pharmaceutical Compositions Containing Them
US20080242710A1 (en) 2005-10-06 2008-10-02 Karl Baumann Pharmaceutically Active Tetrahydro-Pyrrolo[1,2-B]Isothiazole 1,1-Dioxides
US20080249157A1 (en) 2005-04-15 2008-10-09 Dominion Pharmakine S.L. Novel Inhibitors of the Lfa-1/Icam-1 Interaction and Uses Thereof

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872A (en) 1849-11-13 Means of changing the combination in bevolving tumbler-locks
US735A (en) 1838-05-10 Rtjftjg porter
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4316893A (en) * 1975-06-19 1982-02-23 Nelson Research & Development Co. Vehicle composition containing 1-substituted azacycloalkan-2-ones
US4405616A (en) 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4557934A (en) 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
US4568343A (en) * 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US4713244A (en) 1985-08-16 1987-12-15 Bausch & Lomb Incorporated Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent
US4931279A (en) * 1985-08-16 1990-06-05 Bausch & Lomb Incorporated Sustained release formulation containing an ion-exchange resin
US4668506A (en) * 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
ATE114972T1 (de) 1987-11-02 1994-12-15 Baylor College Medicine Verwendung von icam-1 oder ihre funktionelle derivate zur behandlung unspezifischer entzündungen.
DE68907066T2 (de) 1988-01-29 1993-12-16 Koken Kk Verbesserte Formulierungen mit kontrollierter Abgabe.
DE3802996A1 (de) * 1988-02-02 1989-08-10 Cassella Ag Verwendung von 2-oxo-pyrrolidin-1-acetamid zur bestimmung der glomerulaeren filtrationsrate beim menschen
US5424399A (en) * 1988-06-28 1995-06-13 The Children's Medical Center Corporation Human CR3α/β heterodimers
ATE123810T1 (de) 1988-08-23 1995-06-15 Dana Farber Cancer Inst Inc Alpha-subeinheit des lfa-1-leukocyt-adhäsions- rezeptors.
EP0362531B1 (en) 1988-09-01 1999-11-10 Bayer Corporation A human rhinovirus receptor protein that inhibits virus infectivity
KR900701846A (ko) 1988-09-28 1990-12-04 원본미기재 세포간 점착분자 및 이의 결합 리간드
US5149780A (en) 1988-10-03 1992-09-22 The Scripps Research Institute Peptides and antibodies that inhibit integrin-ligand binding
EP0462184A4 (en) 1989-03-09 1992-01-08 Dana Farber Cancer Institute Method of treating viral infections using lfa-1
AU5553290A (en) 1989-04-28 1990-11-29 Baylor College Of Medicine Dissemination of hiv-1 infected cells
CH679207A5 (cg-RX-API-DMAC10.html) * 1989-07-28 1992-01-15 Debiopharm Sa
WO1991019511A1 (en) 1990-06-18 1991-12-26 The General Hospital Corporation CONTROLLING CELLULAR IMMUNE/INFLAMMATORY RESPONSES WITH β2 INTEGRINS
CA2046830C (en) 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
US5318965A (en) 1990-08-24 1994-06-07 Abbott Laboratories Quinobenzoxazine, antineoplastic agents
JPH06500555A (ja) 1990-08-27 1994-01-20 カイロン コーポレイション 病気の処置のためのペプチドの薬物
US5288854A (en) * 1990-11-28 1994-02-22 Center For Blood Research, Inc. Functional derivatives of ICAM-1 which are substantially capable of binding to LFA-1 but are substantially incapable of binding to MAC-1
CH683149A5 (fr) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
AU2777092A (en) * 1991-10-04 1993-05-03 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Treatment of ocular inflammation by blockage of cell adhesion molecules
US6764681B2 (en) * 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US6162432A (en) 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
WO1993017047A1 (en) * 1992-02-28 1993-09-02 Board Of Regents, The University Of Texas System Compositions and methods for the treatment of thermal injury
GB9211268D0 (en) 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
US5298492A (en) 1992-08-04 1994-03-29 Schering Corporation Diamino acid derivatives as antihypertensives
CA2140933A1 (en) 1992-08-21 1994-02-22 Paula M. Jardieu Method for treating an lfa-1 mediated disorder
DK0661989T3 (da) * 1992-09-21 1998-03-02 Upjohn Co Proteinsammensætninger med vedvarende frigivelse
WO1994011400A1 (en) 1992-11-18 1994-05-26 Helsinki University Licensing Ltd. Oy Peptides from human icam-2 and from human icam-1 and their analogs for use in therapy and diagnosis
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
PL174772B1 (pl) 1993-01-06 1998-09-30 Kinerton Ltd Kompozycja farmaceutyczna zawierająca jonowy konjugat cząsteczkowy
US5424289A (en) * 1993-07-30 1995-06-13 Alza Corporation Solid formulations of therapeutic proteins for gastrointestinal delivery
US5397791A (en) * 1993-08-09 1995-03-14 Merck & Co., Inc. Fibrinogen receptor antagonists
DE59409322D1 (de) 1993-12-03 2000-06-08 Hoffmann La Roche Essigsäurederivate als Arzneimittel
US5470953A (en) 1993-12-23 1995-11-28 Icos Corporation Human β2 integrin α subunit
US5849327A (en) 1994-07-29 1998-12-15 Advanced Polymer Systems, Inc. Delivery of drugs to the lower gastrointestinal tract
US5585359A (en) 1994-09-29 1996-12-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
ATE170179T1 (de) * 1994-11-02 1998-09-15 Merck Patent Gmbh Adhäsionsrezeptor-antagonisten
US20020028798A1 (en) 1995-12-12 2002-03-07 Omeros Medical Systems Irrigation solution and method for inhibition of pain and inflammation
US5612052A (en) * 1995-04-13 1997-03-18 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
JP3133073B2 (ja) 1995-05-29 2001-02-05 ファイザー・インコーポレーテッド 成長ホルモンの放出を促進するジペプチド類
US5877224A (en) * 1995-07-28 1999-03-02 Rutgers, The State University Of New Jersey Polymeric drug formulations
US5863910A (en) * 1996-01-12 1999-01-26 Bolonick; Joel Treatment of chronic inflammatory disorders of the gastrointestinal tract
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
IL126422A (en) 1996-04-23 2004-02-19 Kinerton Ltd Biodegradable acidic polylactic polymers and methods for their preparation
HRP970493A2 (en) 1996-09-23 1998-08-31 Wienman E. Phlips Oral delayed immediate release medical formulation and method for preparing the same
CA2217134A1 (en) * 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
PT944619E (pt) * 1996-11-27 2007-01-31 Bristol Myers Squibb Pharma Co Novos antagonistas dos receptores da integrina
US5968895A (en) 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US5893985A (en) * 1997-03-14 1999-04-13 The Lincoln Electric Company Plasma arc torch
AR012443A1 (es) 1997-04-16 2000-10-18 Uriach & Cia Sa J Nuevas carboxamidas como inhibidores de la agregacion plaquetaria, procedimiento para su preparacion, composiciones farmaceuticas que loscontienen y uso de los mismos en la manufactura de medicamentos
US6541606B2 (en) * 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
CA2352389C (en) 1998-11-27 2009-01-20 Kanji Takada An oral formulation for gastrointestinal drug delivery
IT1304152B1 (it) 1998-12-10 2001-03-08 Mediolanum Farmaceutici Srl Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato
NZ511219A (en) 1999-01-05 2003-05-30 Univ Southern Australia Novel agents and methods for treatment and diagnosis of ocular disorders
WO2000044731A1 (en) 1999-01-27 2000-08-03 G.D. Searle & Co. Novel hydroxyamidino carboxylate derivatives useful as nitric oxide synthase inhibitors
EP1028114A1 (en) * 1999-02-13 2000-08-16 Aventis Pharma Deutschland GmbH Novel guanidine derivatives as inhibitors of cell adhesion
US20010006656A1 (en) * 1999-02-17 2001-07-05 University Of Washington Methods and compositions for inhibiting inflammation associated with pulmonary disease
MX339071B (es) 1999-03-31 2016-05-09 Janssen Pharmaceutica Nv Almidon pregelatinizado en una formulacion de liberacion controlada.
WO2000072883A2 (en) 1999-06-02 2000-12-07 Aviana Biopharm Pharmaceutical transdermal compositions
WO2001001964A2 (en) 1999-06-23 2001-01-11 Sedum Laboratories, Inc. Ionically formulated biomolecule microcarriers
JP4303438B2 (ja) 1999-08-18 2009-07-29 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス ペプチドの持続放出製剤
ECSP003707A (es) 1999-10-13 2002-05-23 Novartis Ag Diazepanes
US6605597B1 (en) 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
US6294522B1 (en) 1999-12-03 2001-09-25 Cv Therapeutics, Inc. N6 heterocyclic 8-modified adenosine derivatives
EP1237575B1 (en) 1999-12-14 2008-08-06 Genentech, Inc. Tnf-alpha antagonist and lfa-1 antagonist for treating rheumatoid arthritis
US7521061B2 (en) * 1999-12-31 2009-04-21 Rutgers, The State University Of New Jersey Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix
WO2001049249A2 (en) 1999-12-31 2001-07-12 Rutgers, The State University Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix
JP4917726B2 (ja) 1999-12-31 2012-04-18 ルトガーズ、ザ ステイト ユニバーシティ オブ ニュージャージー ポリマー混合物および活性化合物からなる徐放用医薬製剤
US20030064105A1 (en) * 2000-08-25 2003-04-03 Myung-Jin Kim Lipophilic-coated microparticle containing a protein drug and formulation comprising same
EP1296943A1 (fr) 2000-05-05 2003-04-02 Societe De Conseils De Recherches Et D'applications Scientifiques S.A. (S.C.R.A.S.) Derives d'aminoacides et leur application a titre de medicaments
GB0011817D0 (en) 2000-05-16 2000-07-05 Pharmacia & Upjohn Spa Antagonists of integrin receptors
AR030817A1 (es) 2000-10-02 2003-09-03 Novartis Ag Derivados de diazacicloalcanodiona
GB0025208D0 (en) 2000-10-13 2000-11-29 Euro Celtique Sa Delayed release pharmaceutical formulations
US6653478B2 (en) 2000-10-27 2003-11-25 Ortho-Mcneil Pharmaceutical, Inc. Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators
DE10055857A1 (de) 2000-11-10 2002-08-22 Creative Peptides Sweden Ab Dj Neue pharmazeutische Depotformulierung
GB0028367D0 (en) 2000-11-21 2001-01-03 Celltech Chiroscience Ltd Chemical compounds
WO2002050080A1 (en) 2000-12-19 2002-06-27 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
WO2002058672A2 (en) 2001-01-26 2002-08-01 Debio Recherche Pharmaceutique S.A. Microparticles of biodegradable polymer encapsulating a biologically active substance
DE60216830T2 (de) 2001-02-06 2007-06-14 Pfizer Products Inc., Groton Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
US20030044406A1 (en) * 2001-03-02 2003-03-06 Christine Dingivan Methods of preventing or treating inflammatory or autoimmune disorders by administering CD2 antagonists in combination with other prophylactic or therapeutic agents
JP2005511477A (ja) 2001-03-19 2005-04-28 プラエシス ファーマシューティカルズ インコーポレーテッド 持続放出のための医薬調合物
WO2002089767A1 (en) * 2001-05-03 2002-11-14 Massachusetts Eye And Ear Infirmary Implantable drug delivery device and use thereof
US6872382B1 (en) * 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
KR20040000507A (ko) 2001-05-24 2004-01-03 야마노우치세이야쿠 가부시키가이샤 3-퀴놀린-2(1h)-일리덴인돌린-2-온 유도체
JP4583751B2 (ja) 2001-06-06 2010-11-17 アベンティス・フアーマ・リミテッド 炎症性疾患の治療に使用するための置換されたテトラヒドロイソキノリン
AU2002320352A1 (en) 2001-07-24 2003-02-17 Biogen Idec Ma Inc. Methods for treating or preventing sclerotic disorders using cd2-binding agents
HRP20040406A2 (en) * 2001-11-09 2005-02-28 Eyetech Pharmaceuticals Methods for treating ocular neovascular diseases
IL162293A0 (en) 2001-12-19 2005-11-20 Alza Corp Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
KR20040091100A (ko) 2002-03-04 2004-10-27 소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. 운반체 펩타이드를 함유하는 서방형 의약 조성물
WO2003103587A2 (en) * 2002-06-06 2003-12-18 Dana-Farber Cancer Institute Compounds or agents that inhibit and induce the formation of focal microvessel dilatations
WO2004014365A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Phthalimide derivatives as matrix metalloproteinase inhibitors
JP2006502183A (ja) 2002-09-20 2006-01-19 アルコン,インコーポレイテッド ドライアイ障害の処置のためのサイトカイン合成インヒビターの使用
US7785578B2 (en) 2002-10-11 2010-08-31 Aciont, Inc. Non-invasive ocular drug delivery
JP2007524349A (ja) * 2003-01-16 2007-08-30 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア ICAM−1のsiRNA阻害のための組成物及び方法
JP4709552B2 (ja) * 2003-02-19 2011-06-22 邦康 早田 Lfa−1抑制剤、及びその用途
EP1622609A4 (en) * 2003-04-29 2008-09-03 Smithkline Beecham Corp METHODS OF TREATING DEGENERATIVE DISEASES / LESIONS
WO2005010024A2 (en) 2003-07-22 2005-02-03 Science & Technology Corporation @ Unm Potent peptide inhibitors and methods of use
US7544699B2 (en) 2003-08-08 2009-06-09 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
WO2005014532A1 (en) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
SG146624A1 (en) * 2003-09-11 2008-10-30 Kemia Inc Cytokine inhibitors
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
WO2005042710A1 (en) 2003-10-28 2005-05-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of statin to kill ebv-transformed b cells
WO2005065668A2 (en) * 2003-12-29 2005-07-21 Qlt Usa, Inc. Topical compositions comprising halo-deoxyadenosines for treatment of skin disorders
KR100799802B1 (ko) * 2004-02-04 2008-01-31 화이자 프로덕츠 인크. 치환된 퀴놀린 화합물
UA86051C2 (en) 2004-02-04 2009-03-25 Пфайзер Продактс Инк. Substituted quinoline compounds
GT200500139A (es) 2004-06-08 2005-07-25 Metodo para la preparacion de acidos hidroxamicos
EP1756163A2 (en) * 2004-06-09 2007-02-28 Genentech, Inc. Method of treating granuloma annulare or sarcoid
US20060089590A1 (en) 2004-10-27 2006-04-27 John Higuchi Methods and devices for sustained in-vivo release of an active agent
US20060286108A1 (en) 2005-06-16 2006-12-21 Bell Katherine A Topical compositions for the treatment of chronic wounds
DE102005029746B4 (de) * 2005-06-24 2017-10-26 Boehringer Ingelheim International Gmbh Zerstäuber
US8097237B2 (en) * 2005-08-23 2012-01-17 Stc.Unm Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma
JP2007099641A (ja) * 2005-09-30 2007-04-19 Tsumura & Co インドールキノキサリン類化合物、その製造方法およびそれを用いた医薬組成物
US20080262070A1 (en) * 2005-10-06 2008-10-23 Karl Baumann Pharmaceutically Active Tetrahydro-Pyrrolizinone Compounds
WO2007076358A1 (en) * 2005-12-23 2007-07-05 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
CA2702984C (en) 2007-10-19 2017-04-11 Sarcode Corporation Compositions and methods for treatment of diabetic retinopathy
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
EP3632444A3 (en) 2008-04-15 2020-08-26 SARcode Bioscience Inc. Topical lfa-1 antagonists for use in localized treatment of immune related disorders
EP2276508A4 (en) 2008-04-15 2011-12-28 Sarcode Bioscience Inc ADMINISTRATION OF LFA-1 ANTAGONISTS TO THE GASTROINTESTINAL SYSTEM
US8378105B2 (en) * 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof

Patent Citations (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5135916A (en) 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
US5624837A (en) 1994-03-03 1997-04-29 Alexion Pharmaceuticals, Inc. Nucleic acid encoding chimeric complement inhibitor proteins
US5843885A (en) 1994-04-19 1998-12-01 The University Of Kansas ICAM-1/LFA-1 short-chain peptides and method of using same
US5747035A (en) 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US5843884A (en) 1995-11-15 1998-12-01 Oklahoma Medical Research Foundation C9 complement inhibitor
US6319897B1 (en) 1996-03-13 2001-11-20 John D. Lambris Peptides which inhibit complement activation
US6630492B1 (en) 1997-08-28 2003-10-07 Novartis Ag Lymphocyte function antigen-1 antagonists
US7166568B1 (en) 1998-02-09 2007-01-23 Oklahoma Medical Research Foundation Compositions and methods to inhibit formation of the C5b-9 complex of complement
WO1999049856A2 (en) 1998-03-27 1999-10-07 Genentech, Inc. Antagonists for treatment of cd11/cd18 adhesion receptor mediated disorders
US20050203135A1 (en) 1998-03-27 2005-09-15 Genentech, Inc. Antagonists for treatment of CD/11CD18 adhesion receptor mediated disorders
US20050080119A1 (en) 1998-10-13 2005-04-14 Nader Fotouhi Diaminopropionic acid derivatives
US6803384B2 (en) 1998-10-13 2004-10-12 Hoffmann-La Roche Inc. Diaminopropionic acid derivatives
US7217728B2 (en) 1998-10-13 2007-05-15 Hoffmann-La Roche Inc. Diaminopropionic acid derivatives
US6331640B1 (en) 1998-10-13 2001-12-18 Hoffmann-La Roche Inc. Diaminopropionic acid derivatives
WO2000021920A1 (en) 1998-10-13 2000-04-20 F. Hoffmann-La Roche Ag Diaminopropionic acid derivatives
US20040116518A1 (en) 1998-12-29 2004-06-17 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
US20040028648A1 (en) 1998-12-30 2004-02-12 The Children's Medical Center Corporation Prevention and treatment of retinal ischemia and edema
US6818638B2 (en) 1999-02-16 2004-11-16 Novartis Ag Melvinolin derivatives
US6630447B2 (en) 2000-01-14 2003-10-07 University Of New Mexico Peptide inhibitors of LFA-1/ICAM-1 interaction
US6515124B2 (en) 2000-02-09 2003-02-04 Hoffman-La Roche Inc. Dehydroamino acids
WO2001058853A1 (en) 2000-02-09 2001-08-16 F. Hoffmann-La Roche Ag Dehydroamino acids
US20020156314A1 (en) 2000-06-29 2002-10-24 Link James T. Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents
US20050014746A1 (en) 2000-06-29 2005-01-20 Icos Corporation Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-supressive agents
US20070066585A1 (en) 2000-06-29 2007-03-22 Wang Gary T Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
US20020132807A1 (en) 2000-06-29 2002-09-19 Wang Gary T. Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
US20040058968A1 (en) 2000-11-28 2004-03-25 Genentech, Inc. LFA-1 antagonist compounds
US20020119994A1 (en) 2000-11-28 2002-08-29 Genentech, Inc LFA-1 Antagonist compounds
WO2002059114A1 (en) 2000-11-28 2002-08-01 Genentech, Inc. Lfa-1 antagonist compounds
US6667318B2 (en) 2000-11-28 2003-12-23 Genentech, Inc. LFA-1 antagonist compounds
US6872735B2 (en) 2000-11-28 2005-03-29 Genentech, Inc. LFA-1 antagonist compounds
US20020143035A1 (en) 2000-12-01 2002-10-03 Michele Launay Hydantoin compounds useful as anti-inflammatory agents
US6488916B1 (en) 2001-03-21 2002-12-03 Schering-Plough Healthcare Products, Inc. Skin care compositions
US20040259897A1 (en) 2001-10-01 2004-12-23 Dhar T.G. Murali Spiro-hydantoin compounds useful as anti-inflammatory agents
US20040009998A1 (en) 2001-10-01 2004-01-15 Dhar T. G. Murali Spiro-hydantoin compounds useful as anti-inflammatory agents
US20050004153A1 (en) 2001-10-01 2005-01-06 Dhar T.G. Murali Spiro-hydantoin compounds useful as anti-inflammatory agents
US20040248920A1 (en) 2001-10-01 2004-12-09 Dhar T.G. Murali Spiro-hydantoin compounds useful as anti-inflammatory agents
US20050119279A1 (en) 2003-10-02 2005-06-02 Dhar T. G. M. Spiro-cyclic compounds useful as anti-inflammatory agents
WO2005044817A1 (en) 2003-11-05 2005-05-19 Sunesis Pharmaceuticals, Inc. Modulators of cellular adhesion
US7314938B2 (en) 2003-11-05 2008-01-01 Sunesis Pharmaceuticals, Inc. Modulators of cellular adhesion
US20080234271A1 (en) 2004-04-28 2008-09-25 Icos Corporation Arylphenylamino- and Arylphenylether-Sulfide Derivatives, Useful For the Treatment of Inflammatory and Immune Diseases, and Pharmaceutical Compositions Containing Them
US20060052434A1 (en) 2004-08-18 2006-03-09 Dhar T G M Pyrrolizine compounds useful as anti-inflammatory agents
US20080108677A1 (en) 2004-08-30 2008-05-08 Karyon-Ctt Ltd Thioxothiazolidinone Compounds For Use As Pharmaceuticals
US20060074099A1 (en) 2004-10-01 2006-04-06 Delmonte Albert J Crystalline forms and process for preparing spiro-hydantoin compounds
US20060148836A1 (en) 2004-12-14 2006-07-06 Dhar T G M Pyridyl-substituted spiro-hydantoin compounds and use thereof
US20060142319A1 (en) 2004-12-14 2006-06-29 Bang-Chi Chen Pyridyl-substituted spiro-hydantoin crystalline forms and process
US20080249157A1 (en) 2005-04-15 2008-10-09 Dominion Pharmakine S.L. Novel Inhibitors of the Lfa-1/Icam-1 Interaction and Uses Thereof
US20060281739A1 (en) * 2005-05-17 2006-12-14 Thomas Gadek Compositions and methods for treatment of eye disorders
US20080242710A1 (en) 2005-10-06 2008-10-02 Karl Baumann Pharmaceutically Active Tetrahydro-Pyrrolo[1,2-B]Isothiazole 1,1-Dioxides

Non-Patent Citations (28)

* Cited by examiner, † Cited by third party
Title
"Bioreversible Carriers in Drug Design", 1987, AMERICAN PHARMACEUTICAL ASSOCIATION AND PERGAMON PRESS
"The Science and Practice of Pharmacy", LIPPINCOTT WILLIAMS & WILKINS
A. J. CUNNINGHAM, UNDERSTANDING IMMUNOLOGY, TRANSPLANTATION IMMUNOLOGY, 1978, pages 157 - 159
A. M. JOUSSEN; T. MURATA; A. TSUJIKAWA; B. KIRCHOF; S-E. BURSELL; A. P. ADAMIS: "Leukocyte- Mediated Endothelial Cell Injury and Death in the Diabetic Retina", A, J. PATHOL., vol. 158, no. 1, 2001, pages 147 - 162
CHAVANPATIL, M.D.; JAIN, P.; CHAUDHARI, S.; SHEAR, R.; VAVIA, P.R.: "Novel sustained release, swellable and bioadhesive gastroretentive drug delivery system for olfoxacin", INT. J. PHARM., 2006
FISCHER A; DURANDY A; STERKERS G; GRISCELLI C: "Role of the LFA- molecule in cellular interactions required for antibody production in humans", J. IMMUNOL., vol. 136, 1986, pages 3198
FRENETTE, P. S.: "Locking a leukocyte integrin with statins", N. ENGL. J. MED., vol. 345, 2001, pages 1419 - 1421
GADEK, T. R.; BURDICK, D. J.; MCDOWELL, R. S.; STANLEY, M. S.; MARSTERS, J. C. JR.; PARIS, K. J.; OARE, D. A.; REYNOLDS, M. E.; LA: "Generation of an LFA- antagonist by the transfer of the ICAM- immunoregulatory epitope to a small molecule", SCIENCE, vol. 295, 2002, pages 1086 - 1089, XP002522872, DOI: doi:10.1126/science.295.5557.1086
HOFFMAN, A.; STEPENSKY, D.; LAVY, E.; EYAL, S.; KLAUSNER, E.; FRIEDMAN, M.: "Pharmacokinetic and pharmacodynamic aspects of gastroretentive dosage forms", INT. J. PHARM., vol. 11, 2004, pages 141 - 53
KALLEN, J.; WELZENBACH, K.; RAMAGE, P.; GEYL, D.; KRIWACKI, R.; LEGGE, G.; COTTENS, S.; WEITZ-SCHMIDT, G.; HOMMEL, U.: "Structural basis for LFA- inhibition upon lovastatin binding to the CD11a I-domain", J. MOL. BIOL., vol. 292, 1999, pages 1 - 9, XP004461886, DOI: doi:10.1006/jmbi.1999.3047
KELLY, T. A.; JEANFAVRE, D. D.; MCNEIL, D. W.; WOSKA, J. R. JR.; REILLY, P. L.; MAINOLFI, E. A.; KISHIMOTO, K. M.; NABOZNY, G. H.;: "Cutting edge: a small molecule antagonist of LFA-1-mediated cell adhesion", J. IMMUNOL., vol. 163, 1999, pages 5173 - 5177, XP002171606
KLAUSNER, E.A.; LAVY, E.; BARTA, M.; CSEREPES, E.; FRIEDMAN, M.; HOFFMAN, A.: "Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on levodopa in humans", PHARM. RES., vol. 20, 2003, pages 1466 - 73
KUYPERS T.W.; ROOS D.: "Leukocyte membrane adhesion proteins LFA-1, CR3 and pl50,95: a review of functional and regulatory aspects", RES. IMMUNOL., vol. 140, 1989, pages 461 - 465
LANDEGREN, U., J. IMMUNOL. METHODS, vol. 57, 1984, pages 379 - 388
LIU, G.; LINK, J.T.; PEI, Z.; REILLY, E.B.; NGUYEN, B.; MARSH, K.C.; OKASINSKI, G.F.; VON GELDERN, T.W.; ORMES, M.; FOWLER, K.: "Discovery of novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intracellular adhesion molecule- interaction. 1. Identification of an additional binding pocket based on an anilino diaryl sulfide lead", J. MED. CHEM., vol. 43, 2000, pages 4015 - 4030
LO SK; VAN SEVENTER GA; LEVIN SM; WRIGHT SD.: "Two leukocyte receptors (CD1 la/CD18 and CD1 lb/CD18) mediate transient adhesion to endothelium by binding to different ligands", J. IMMUNOL., vol. 143, 1989, pages 3325
LU, C; SHIMAOKA, M.; SALAS, A.; SPRINGER, T.A.: "The Binding Sites for Competitive Antagonistic, Allosteric Antagonistic, and Agonistic Antibodies to the I Domain of Integrin LFA-1", J. IMMUN., vol. 173, 2004, pages 3972 - 3978, XP002461643
MENTZER SJ; GROMKOWSKI SH; KRENSKY AM; BURAKOFF SJ; MARTZ E.: "LFA-1 membrane molecule in the regulation of homotypic adhesions of human B lymphocytesn", J. IMMUNOL., vol. 135, 1985, pages 9
NATURE, vol. 346, 1990, pages 425
S. M. BERGE ET AL., J PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19
S. P. AYALASOMAYAJULA; U. B. KOMPELLA, EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 458, 2003, pages 283 - 289
S.M. KEATING; K.R. CLARK; L. D. STEPANICH; F. ARELLANO; C. P. EDWARDS; S.C. BODARY; S. A. SPENCER; T. R. GADEK; J. C, MARSTERS JR.: "Competition between intercellualr adhesion molecule- and a small molecule antagonist for a common binding site on the al subunit of lymphocyte function-associated antigen-1", PROTEIN SCIENCE, vol. 15, 2006, pages 290 - 303, XP002522873, DOI: doi:10.1110/ps.051583406
SANDERS VM; SNYDER JM; UHR JW; VITETTA ES: "Characterization of the physical interaction between antigen-specific B and T cells", J. IMMUNOL., vol. 137, 1986, pages 2395
SKELLY ET AL.: "FDA and AAPS Report of the Workshop on Principles and Practices of In-Vitro Percutaneous Penetration Studies: Relevance to Bioavailability and Bioequivalence", PHARMACEUTICAL RESEARCH, vol. 4, no. 3, 1987, pages 265 - 276
STREUBEL, A.; SIEPMANN, J.; BODMEIER, R.: "Gastroretentive drug delivery systems", EXPERT OPIN. DRUG DELIVER., vol. 3, 2006, pages 217 - 3, XP009093467, DOI: doi:10.1517/17425247.3.2.217
T. HIGUCHI; V. STELLA: "Pro-drugs as Novel Delivery Systems", vol. 14, A. C. S. SYMPOSIUM SERIES
WEITZ-SCHMIDT, G.; WELZENBACH, K.; BRINKMANN, V.; KAMATA, T.; KALLEN, J.; BRUNS, C.; COTTENS, S.; TAKADA, Y.; HOMMEL, U.: "Statins selectively inhibit leukocyte function antigen- by binding to a novel regulatory integrin site", NATURE MED., vol. 7, 2001, pages 687 - 692
WELZENBACH, K.; HOMMEL, U.; WEITZ-SCHMIDT,G.: "Small molecule inhibitors induce conformational changes in the I domain and the I-like domain of Lymphocyte Function-Associated Antigen-1", J. BIOL. CHEM., vol. 277, 2002, pages 10590 - 10598

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10960087B2 (en) 2007-10-19 2021-03-30 Novartis Ag Compositions and methods for treatment of diabetic retinopathy
US8598156B2 (en) 2010-03-25 2013-12-03 Glaxosmithkline Llc Chemical compounds
US10633384B2 (en) 2012-06-13 2020-04-28 Hoffmann-La Roche Inc. Diazaspirocycloalkane and azaspirocycloalkane
US10669268B2 (en) 2012-09-25 2020-06-02 Hoffmann-La Roche Inc. Bicyclic derivatives
US10913745B2 (en) 2013-03-12 2021-02-09 Hoffmann-La Roche Inc. Octahydro-pyrrolo[3,4-c]-pyrrole derivatives and analogs thereof as autotaxin inhibitors
US10849881B2 (en) 2013-11-26 2020-12-01 Hoffmann-La Roche Inc. Octahydro-cyclobuta[1,2-c;3,4-c′]dipyrrol-2-yl
US11098048B2 (en) 2014-03-26 2021-08-24 Hoffmann-La Roche Inc. Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors
US10654857B2 (en) 2014-03-26 2020-05-19 Hoffman-La Roche Inc. Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors
US10669285B2 (en) 2014-03-26 2020-06-02 Hoffmann-La Roche Inc. Condensed [1,4] diazepine compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors
US11352330B2 (en) 2015-09-04 2022-06-07 Hoffmann-La Roche Inc. Phenoxymethyl derivatives
US10640472B2 (en) 2015-09-04 2020-05-05 Hoffman-La Roche Inc. Phenoxymethyl derivatives
US10889588B2 (en) 2015-09-24 2021-01-12 Hoffmann-La Roche Inc. Bicyclic compounds as dual ATX/CA inhibitors
US10800786B2 (en) 2015-09-24 2020-10-13 Hoffman-La Roche Inc. Bicyclic compounds as ATX inhibitors
US10787459B2 (en) 2015-09-24 2020-09-29 Hoffmann-La Roche Inc. Bicyclic compounds as ATX inhibitors
US10738053B2 (en) 2015-09-24 2020-08-11 Hoffmann-La Roche Inc. Bicyclic compounds as dual ATX/CA inhibitors
US10647719B2 (en) 2015-09-24 2020-05-12 Hoffmann-La Roche Inc. Bicyclic compounds as dual ATX/CA inhibitors
US10882857B2 (en) 2017-03-16 2021-01-05 Hoffmann-La Roche Inc. Bicyclic compounds as ATX inhibitors
US11059794B2 (en) 2017-03-16 2021-07-13 Hoffmann-La Roche Inc. Heterocyclic compounds useful as dual ATX/CA inhibitors
WO2018167113A1 (en) * 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag New bicyclic compounds as atx inhibitors
US11673888B2 (en) 2017-03-16 2023-06-13 Hoffmann-La Roche Inc. Bicyclic compounds as ATX inhibitors
US12357639B2 (en) 2017-09-22 2025-07-15 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
US11833156B2 (en) 2017-09-22 2023-12-05 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
US11426412B2 (en) 2017-10-18 2022-08-30 Jubilant Epipad LLC Imidazo-pyridine compounds as PAD inhibitors
US11629135B2 (en) 2017-11-06 2023-04-18 Jubilant Prodell Llc Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
US11459338B2 (en) 2017-11-24 2022-10-04 Jubilant Episcribe Llc Heterocyclic compounds as PRMT5 inhibitors
US11529341B2 (en) 2018-03-13 2022-12-20 Jubilant Prodel LLC Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation
US11274095B2 (en) 2018-04-18 2022-03-15 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US10689371B2 (en) 2018-04-18 2020-06-23 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US12612390B2 (en) 2018-04-18 2026-04-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US11919912B2 (en) 2018-05-21 2024-03-05 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US12516040B2 (en) 2019-07-24 2026-01-06 Constellation Pharmaceuticals, Inc. Crystalline forms of 7-chloro-2-(4-3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide

Also Published As

Publication number Publication date
CN101873797A (zh) 2010-10-27
JP2011500683A (ja) 2011-01-06
CA2958665A1 (en) 2009-04-30
CA3105972A1 (en) 2009-04-30
JP5808037B2 (ja) 2015-11-10
EP2209371B1 (en) 2017-01-04
ES2830024T3 (es) 2021-06-02
EP2209371A1 (en) 2010-07-28
EP3167886B1 (en) 2020-08-05
AU2008317473B2 (en) 2014-07-17
CA2702984A1 (en) 2009-04-30
ES2630406T3 (es) 2017-08-21
EP3167886A1 (en) 2017-05-17
US20090155176A1 (en) 2009-06-18
CA2958665C (en) 2021-03-02
CA2702984C (en) 2017-04-11
US10960087B2 (en) 2021-03-30
EP2209371A4 (en) 2011-11-02
AU2008317473A1 (en) 2009-04-30
US20210338839A1 (en) 2021-11-04
JP2014221808A (ja) 2014-11-27
EP3797775A1 (en) 2021-03-31
US20160220702A1 (en) 2016-08-04
MX2010004281A (es) 2010-09-10

Similar Documents

Publication Publication Date Title
US20210338839A1 (en) Compositions and methods for treatment of diabetic retinopathy
US12558350B2 (en) Compositions and methods for treatment
HK40043039A (en) Compositions and methods for treatment of diabetic retinopathy
HK1236853B (en) Compositions and methods for treatment of macular edema
HK1236853A1 (en) Compositions and methods for treatment of macular edema
AU2014208186A1 (en) Compositions and methods for treatment of diabetic retinopathy
HK1149902A (en) Compositions and methods for treatment of diabetic retinopathy
HK1241744A1 (en) Compositions and methods for treatment of dry eye disorders

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880117716.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08842113

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2702984

Country of ref document: CA

Ref document number: 2010529955

Country of ref document: JP

Ref document number: 2008317473

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/004281

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2008842113

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008842113

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008317473

Country of ref document: AU

Date of ref document: 20081017

Kind code of ref document: A